Ad-hoc Announcements

Archive:
Insider Information according to Article 17 MAR dated September 27, 2021, 08:22 AM

aap Implantate AG resolves on capital increase with subscription rights to finance sales growth and start of human clinical study for antibacterial silver coating technology

aap Implantate AG resolves on capital increase with subscription rights to finance sales growth and start of human clinical study for antibacterial silver coating technology

aap Implantate AG / Key word(s): Capital Increase/Financing
aap Implantate AG resolves on capital increase with subscription rights to finance sales growth and start of human clinical study for antibacterial silver coating technology

27-Sep-2021 / 08:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Management Board of aap Implantate AG ("aap" or the "Company") resolved on 27 September 2021 with the approval of the Supervisory Board of the same day on a capital increase against cash contributions out of the authorized capital 2019/I with subscription and oversubscription rights of the shareholders of the Company. aap's share capital shall be increased by up to EUR 1,500,000.00 by issuing up to 1,500,000 new no-par value bearer shares from the current amount of EUR 3,478,243.00 to up to EUR 4,978,243.00. The new shares shall be offered to the shareholders of the Company at a subscription price of EUR 3.30 per new share based on a subscription ratio of 2.3189:1. The new shares are entitled to participate in dividends as of 1 January 2021.
 

At the present time, aap has commitments from its shareholders to exercise subscription and oversubscription rights and commitments from new investors to subscribe for new shares in the private placement with a total volume of approx. EUR 2.7 million. This corresponds to approx. 54% of the capital increase.
 

The issue proceeds from the transaction shall be used to finance the planned sales growth with a focus on the USA (especially investments in sets) and the start of the human clinical study for the Company's antibacterial silver coating technology in the fourth quarter of 2021.
 

The new shares will be offered to the shareholders of aap for subscription by way of an indirect subscription right during a subscription period. The subscription period is expected to start on 4 October 2021 (00.00 hours CEST) and to end on 18 October 2021 (24.00 hours CEST). No trading of subscription rights will be organized and subscription rights which are not exercised will expire worthless. In addition to exercising their subscription rights, all shareholders of the Company have the option to participate in the capital increase within an oversubscription. These oversubscription rights must also be exercised during the subscription period. New shares, which are not subscribed as part of the subscription offer, shall be offered to investors for sale by means of a private placement at a price at least equaling the subscription price per new share.
 

The capital increase with subscription rights is accompanied by BankM AG. For further details regarding the transaction please refer to the subscription offer, which will be published before the start of the subscription period on the corporate website of the Company (https://www.aap.de/) in the section "Investors / Capital Increase" as well as in the Federal Gazette under https://www.bundesanzeiger.de/.


 

-------------------------------------------------------------------------------------------------------------------------------------------
aap
Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
 

For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: f.franke@aap.de

27-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated September 16, 2021, 01:36 PM

aap Implantate AG significantly raises EBITDA forecast for financial year 2021

aap Implantate AG significantly raises EBITDA forecast for financial year 2021

aap Implantate AG / Key word(s): Change in Forecast/Annual Results
aap Implantate AG significantly raises EBITDA forecast for financial year 2021

16-Sep-2021 / 13:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap" or the "Company") announces that the EBITDA guidance for the financial year 2021 is increased significantly by approx. 64% up to approx. 80% to a range between EUR -2.0 million and EUR -0.7 million. This is due to lower overall operating expenses, which will be incurred to a substantially lower extent as a result of strict cost discipline, and in particular a noticeably reduced cost framework for the planned human clinical study for the antibacterial silver coating technology. The cost reduction in connection with the human study results, on the one hand, from the decision to build up important know-how internally and thus to carry out the study with a higher proportion of own work. On the other hand, after re-evaluation of all available findings and renegotiation of contracts, the total cost of the study could be significantly reduced. In addition, the COVID-19-related postponement of the start of the human clinical study to the fourth quarter of 2021 means that a lower proportion of the costs will be incurred in the current financial year 2021 than was originally planned.
 

Against the backdrop of these developments, aap adjusts the outlook for the financial year 2021 and expects EBITDA in the range of EUR -2.0 million to EUR -0.7 million (previously: EUR -5.5 million to EUR -3.5 million) based on a now narrowed sales level of EUR 12.0 million to EUR 14.0 million (previously: EUR 12.0 million to EUR 15.0 million). Excluding R&D project costs for the silver coating and resorbable magnesium implant technologies, the forecast values for EBITDA are now between EUR -1.1 million and EUR +0.2 million (previously: EUR -2.8 million to EUR -0.8 million).


 

-------------------------------------------------------------------------------------------------------------------------------------------
aap
Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

 

For queries, please contact:

aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: f.franke@aap.de

16-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated May 19, 2021, 12:20 PM

aap Implantate AG: Significant year-on-year earnings improvement (+91%) in Q1/2021 with almost balanced EBITDA (EUR -0.2 million)

aap Implantate AG: Significant year-on-year earnings improvement (+91%) in Q1/2021 with almost balanced EBITDA (EUR -0.2 million)

aap Implantate AG / Key word(s): Quarter Results
aap Implantate AG: Significant year-on-year earnings improvement (+91%) in Q1/2021 with almost balanced EBITDA (EUR -0.2 million)

19-May-2021 / 12:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap" or "Company") achieved EBITDA of EUR -0.2 million in Q1/2021, significantly above the level in the corresponding period of the previous year (Q1/2020: EUR -2.2 million). Excluding one-time effects, recurring EBITDA in the first quarter of 2021 also improved noticeably year-on-year to EUR -0.2 million (Q1/2020: EUR -1.4 million). The background to this development, in connection with the 9% sales growth to EUR 2.7 million realized in the reporting period, is a significant increase in the gross margin[1] and a strongly reduced cost level. In addition, EBITDA in the first three months of 2021 were positively impacted by an effect in other operating income, primarily due to the recognition in income of a first partial payment from the COVID-19 aid program "Überbrückungshilfe III". Overall, the significant improvement in EBITDA thus visibly reflects the progress realized in the ongoing restructuring.
 

Based on the development in the first quarter, the Management Board is confident that as the COVID-19 pandemic continues to subside in conjunction with the withdrawal of the lockdown measures and thus the opening of the markets, a further dynamization of sales will occur in the coming quarters and thus positive EBITDA can be achieved in the operating trauma business for the first time since the focus on trauma. Accordingly, aap expects sales growth for the second quarter of 2021 and plans a sales level above the EUR 3 million mark (Q2/2020: EUR 1.9 million, H1/2020: EUR 4.4 million). However, based on the current order situation, this only applies under the condition that the COVID-19 pandemic continues to ease, and no additional drastic lockdown measures are imposed.
 

For a more detailed presentation of the main developments in the first quarter of 2021, aap will publish a press release in the coming days.



[1] Gross margin = sales revenues +/- change in inventories of finished goods and work in progress less cost of materials / cost of purchased services.

-------------------------------------------------------------------------------------------------------------------------------------------
aap
Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
 

For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: f.franke@aap.de
 

19-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated April 29, 2021, 04:26 PM

Refusal of audit opinions for annual financial report 2020 (HGB) and consolidated annual financial report 2020 (IFRS); measures to secure further financing in implementation

Refusal of audit opinions for annual financial report 2020 (HGB) and consolidated annual financial report 2020 (IFRS); measures to secure further financing in implementation

aap Implantate AG / Key word(s): Miscellaneous
Refusal of audit opinions for annual financial report 2020 (HGB) and consolidated annual financial report 2020 (IFRS); measures to secure further financing in implementation

29-Apr-2021 / 16:26 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap" or "Company") was informed at today's balance sheet meeting that the auditor Mazars GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Hamburg, will refuse the audit opinions for the annual financial report 2020 (HGB) and the consolidated annual financial report 2020 (IFRS). The background to this is that in the auditor's view up to the time of today's balance sheet meeting no sufficient evidence could be presented that aap's financing is secured for the twelve-month period. As a result, the auditor will declare the non-issuance of audit opinions due to an audit impediment and issue a note of refusal. In this case too, the Supervisory Board will adopt the annual financial statements (HGB) for the 2020 financial year and approve the consolidated financial statements (IFRS) for the 2020 financial year. The publication of the annual financial report 2020 (HGB) and the consolidated annual financial report 2020 (IFRS) is scheduled for April 30, 2021.
 

aap is still undergoing a comprehensive restructuring and refinancing process to secure further financing and thus the Company's continued existence. In this context, aap was already able to make noticeable progress in restructuring in financial year 2020, which is reflected, among other things, in a significantly improved recurring EBITDA (EUR -3.4 million; +28% vs. FY/2019) despite the enormous challenges posed by the COVID 19 pandemic. This improvement was mainly achieved through dynamic sales growth in the US (+41 % vs. FY/2019), an increased gross margin and a significantly reduced cost level. In addition, the Company was able to successfully implement the first two steps of the refinancing with a capital reduction and the issue of a convertible bond in the amount of EUR 2.6 million. In addition, aap has noticeably reduced the repayment amounts for the next few years by selling off excess capacity in its machinery and has raised shareholder loans of EUR 0.4 million.
 

In the first four months of financial year 2021, the focus was again on securing the Company's future financing. Further measures were implemented to ensure the continuity of the Company and to finance the planned growth and further development of the key technologies. In this context, at the end of March 2021 aap signed a purchase agreement with a Berlin real estate company for the sale of a plot of land in Brandenburg and qualified for the first time to receive state Corona aid under the COVID 19 aid program "Überbrückungshilfe III". aap has already received funds of EUR 0.5 million from the above financing measures, and further funds of around EUR 0.4 million will flow into the Company in the short term if both financing measures are successfully completed. In addition, the Management Board is currently working on the implementation of further measures and is confident that it will be able to implement them successfully and thus secure aap's financing over the next twelve months in line with current business planning.

 

-------------------------------------------------------------------------------------------------------------------------------------------
aap
Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

 

For queries, please contact:

aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: f.franke@aap.de

29-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated October 26, 2020, 06:52 PM

aap Implantate AG: Significant year-on-year improvement in Q3/2020 earnings with almost balanced EBITDA - EBITDA forecast for the full year raised

aap Implantate AG: Significant year-on-year improvement in Q3/2020 earnings with almost balanced EBITDA - EBITDA forecast for the full year raised

aap Implantate AG / Key word(s): Change in Forecast/9 Month figures
aap Implantate AG: Significant year-on-year improvement in Q3/2020 earnings with almost balanced EBITDA - EBITDA forecast for the full year raised

26-Oct-2020 / 18:52 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Based on preliminary figures, aap Implantate AG ("aap" or "Company") achieved EBITDA in the third quarter of 2020 in the range of EUR -0.2 million to EUR -45K (previous year: EUR -1.7 million). The background to this development are, with sales almost stable, mainly a significant reduction in the cost level as a result of a comprehensive restructuring and efficiency enhancement program, a special effect from foreign currency effects in the context of intragroup transactions with the U.S. subsidiary aap Implants Inc. within inventories and a margin improvement due to the dynamic growth of the U.S. business.
 

Overall, EBITDA after nine months thus amount to between EUR -4.6 million and EUR -4.4 million (previous year: EUR -4.9 million) with sales revenues of EUR 6.9 million (previous year: EUR 8.7 million) despite noticeable effects of the COVID-19 pandemic and comprehensive restructuring expenses.
 

Due to the strong earnings development in the third quarter of 2020 aap is raising its EBITDA forecast. For the financial year 2020 aap now expects EBITDA of EUR -5.9 million to EUR -4.5 million (previously EUR -6.7 million to EUR -5.5 million). From today's perspective, the Company continues to expect sales revenues in the upper half of the guidance of EUR 8 million to EUR 10 million in fiscal year 2020. The adjusted forecast assumes that there will be no comprehensive lockdown measures due to the COVID-19 pandemic in the remaining fiscal year 2020. A more detailed press release on the key developments in the third quarter and first nine months of 2020 will be issued later this week.


 

-----------------------------------------------------------------------------------------------------------------------------------------

aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock exchanges -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, produces and markets products for traumatology. The IP-protected portfolio includes the innovative anatomical plate system LOQTEQ(R) and a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical and as yet unsolved problems in traumatology. aap Implantate AG sells its products in Germany directly to hospitals, purchasing groups and affiliated clinics, while at international level it primarily uses a broad network of distributors in some 25 countries. In the U.S. the company and its subsidiary aap Implants Inc. are pursuing a hybrid sales strategy. Sales are made both through distribution agents and in partnership with global orthopedic companies. aap Implantate AG stock is listed in the General Standard segment of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information please visit our website at www.aap.de.
 

Future-oriented statements
This release may contain forward-looking statements based on the current expectations, presumptions and forecasts of the Management Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of the future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those described by aap in published reports. Forward-looking statements therefore only apply on the day on which they are made. We assume no obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.
 

For further information please contact:

aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49/30/750 19 - 134; Fax: +49/30/750 19 - 290; Email: f.franke@aap.de
 

26-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated August 05, 2020, 07:10 PM

aap Implantate AG offers its shareholders a convertible bond with a total nominal value of EUR 2.6 million; attractive offer and a major step toward securing the company's continued existence

aap Implantate AG offers its shareholders a convertible bond with a total nominal value of EUR 2.6 million; attractive offer and a major step toward securing the company's continued existence

aap Implantate AG / Key word(s): Financing
aap Implantate AG offers its shareholders a convertible bond with a total nominal value of EUR 2.6 million; attractive offer and a major step toward securing the company's continued existence

05-Aug-2020 / 19:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Management Board of aap Implantate AG ("aap" or the "Company") resolved today, with the Supervisory Board's approval of the same day, on making use of the General Meeting's authorization granted on June 21, 2019 to issue convertible bonds and to issue, making partial use of the authorization, an unsubordinated and unsecured convertible bond 2020/2023 with a total nominal value of up to EUR 2,550,814.00. The convertible bond is divided into up to 1,457,608 convertible bonds with a nominal value of EUR 1.75 each. The shareholders are granted a subscription right to the convertible bonds and the possibility of over-subscription.
 

The convertible bond has a term of three years, provides for an annual fixed interest rate of 6.00% and, in accordance with the bond terms and conditions, entitles to subscribe to a total of up to 1,457,608 ordinary bearer shares (no-par shares) in aap Implantate AG at an initial conversion price of EUR 1.75. The convertible bond is taken over by BankM AG, Frankfurt am Main, with the obligation to offer it to the Company's shareholders for subscription at a ratio of 22:1 (22 shares each entitle to subscribe to one convertible bond with a nominal value of EUR 1.75) at an issue price of EUR 1.75 per convertible bond within the subscription period. In this way aap Implantate AG offers its shareholders the opportunity to participate in the financing measure at an attractive discount on the anticipated future share price after the ordinary capital reduction to be resolved by the Company's (virtual) Annual General Meeting on August 7, 2020 and subsequently to be entered in the Commercial Register.
 

At the present time aap Implantate AG has obligations from among its shareholders to exercise subscription and over-subscription rights totaling EUR 1,250,000.00. This corresponds to about 50% of the convertible bond.
 

The convertible bond is an essential part of the refinancing and restructuring process currently being implemented by aap Implantate AG and serves to secure the Company's continued existence. Consequently, the issuance proceeds from the convertible bond are to be used to secure the Company's liquidity in the short term. In addition, the Management Board is currently working intensively on various other financing and cost-saving options. In particular, these include a committed interest-free loan from Investitionsbank Berlin (IBB) from the "Rescue Aid Corona Emergency Aid Package I" program, which is subject to certain challenging conditions, a possible partial sale of excess capacity of the machinery, as well as far advanced negotiations on concluding a development and supply contract with a world-leading U.S. medical technology company, which is linked to the availability of sufficient financial resources at least for the duration of the development project. At the same time, the Management Board is currently in talks about possible corporate transactions (e.g. mergers, share or asset deals and carve-outs).
 

Shareholders can exercise their subscription rights during the subscription period, which is expected to begin on August 12, 2020 (0:00 hours CEST) and is expected to end on August 26, 2020 (24:00 hours CEST). No subscription rights trading will be organized, and subscription rights not exercised will expire worthless. In addition, all shareholders of the Company have the option to acquire convertible bonds in addition to the exercise of their subscription rights in the context of an over-subscription. These over-subscription rights must also be exercised within the subscription period. Any bonds not subscribed for as a result of the subscription offer shall be offered for purchase to institutional investors in Germany and other European countries in a private placement, whereby the purchase price corresponds to the subscription price.
 

The convertible bond is accompanied by BankM AG. Further details can be taken from the subscription offer, which is expected to be published in the Federal Gazette on August 10, 2020. From that date, it will also be available on the Company's website (https://www.aap.de/) under the section "Investors / Convertible Bond".

 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49/30/750 19 - 134; Fax: +49/30/750 19 - 290; f.franke@aap.de
 

05-Aug-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated June 29, 2020, 08:48 PM

aap Implantate AG: Refusal of audit opinions for annual financial report 2019 (HGB) and consolidated annual financial report 2019 (IFRS); implementation of various financing and cost-saving options to secure financing

aap Implantate AG: Refusal of audit opinions for annual financial report 2019 (HGB) and consolidated annual financial report 2019 (IFRS); implementation of various financing and cost-saving options to secure financing

aap Implantate AG / Key word(s): Miscellaneous
aap Implantate AG: Refusal of audit opinions for annual financial report 2019 (HGB) and consolidated annual financial report 2019 (IFRS); implementation of various financing and cost-saving options to secure financing

29-Jun-2020 / 20:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap" or "Company") was informed at today's balance sheet meeting that the auditor Mazars GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Hamburg, will refuse the audit opinions for the annual financial report 2019 (HGB) and the consolidated annual financial report 2019 (IFRS). The background to this is that in the auditor's view up to the time of today's balance sheet meeting no sufficient evidence could be presented that aap's financing is secured for the twelve-month period. As a result, the auditor will issue a note of refusal due to objections to the accounting on the assumption of continuation of business activity (so-called going concern). In this case too, the Supervisory Board will adopt the annual financial statements (HGB) for the 2019 financial year and approve the consolidated financial statements (IFRS) for the 2019 financial year. The publication of the annual financial report 2019 (HGB) and the consolidated annual financial report 2019 (IFRS) is scheduled for June 30, 2020.
 

aap is currently undergoing a comprehensive restructuring and refinancing process to secure the Company's continued existence and future viability. The already strained liquidity situation has been further exacerbated by the corona pandemic that has led to an enormous impairment of business operations in recent months. Against this background, the Management Board is currently intensively working on the implementation of various financing and cost-saving options. In particular, these include negotiations with the three largest shareholders on a further increase in shareholder loans after initial loans were granted in April. The three main shareholders have already given firm commitments, which are, however, subject to the condition that additional existing or new investors join and participate in the financing. In addition, the Company has received a commitment for an interest-free loan from the Investitionsbank Berlin (IBB) from the "Rescue Aid Corona Emergency Aid Package I" programme, subject to certain conditions. Furthermore, the Company is examining a partial sale of excess capacity of the machinery and is in far advanced negotiations on concluding a development and supply contract with a world-leading U.S. medical technology company. At the same time, the Management Board is currently in talks about possible corporate transactions (e.g. mergers, share or asset deals and carve-outs). If several options can be implemented, aap's financing would be secured.
 

In addition, the Company plans to propose to its shareholders at the Annual General Meeting in the second half of 2020 an ordinary capital decrease. The aim of this measure is to sustainably restructure aap at the financial level and thus to increase flexibility with regard to possible subsequent capital measures. Last but not least, the Management Board aims to reorganize the Company structurally and to align it on the three pillars of its innovative platform technologies in future. In this context, the three technologies LOQTEQ(R), antibacterial silver coating and resorbable magnesium implants shall be transferred to separate subsidiaries and managed independently under the umbrella of aap as a holding company. This makes it possible to manage the individual technologies more flexibly and in a more targeted manner and to implement the co-financing sought for the silver coating and magnesium implant technologies.
 

____________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


For inquiries please contact:

aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49/30/750 19 - 134; Fax: +49/30/750 19 - 290; f.franke@aap.de

29-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated March 16, 2020, 06:49 PM

aap Implantate AG resolves on concept for extensive staff reduction and extraordinary value adjustment to capitalized development costs; postponement of publication of the 2019 financial statements

aap Implantate AG resolves on concept for extensive staff reduction and extraordinary value adjustment to capitalized development costs; postponement of publication of the 2019 financial statements

aap Implantate AG / Key word(s): Restructure of Company/Annual Results
aap Implantate AG resolves on concept for extensive staff reduction and extraordinary value adjustment to capitalized development costs; postponement of publication of the 2019 financial statements

16-March-2020 / 18:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Management Board of aap Implantate AG ("aap") resolved on March 16, 2020 with the approval of the Supervisory Board on the same day on a concept for extensive staff reduction and, in connection with the preparation of the 2019 annual and consolidated financial statements, on making an extraordinary value adjustment to capitalized development costs. In addition, against the background of the evaluation of various strategic alternatives, the Company has decided to postpone the publication of the annual financial report 2019 (HGB) and the consolidated annual financial report 2019 (IFRS) until April 30, 2020.
 

Starting from a headcount of 145 on February 29, 2020, aap plans to reduce its workforce by around 25% in the current financial year. The aim of the measure is to save more than EUR 1.3 million annually in personnel costs from 2021. In connection with this measure, the Company expects one-off expenses of up to EUR 0.7 million, which will have a negative impact on earnings in financial year 2020. In order to make the measure as socially acceptable as possible, the staff reduction is to be carried out in cooperation with a private transfer company.
 

The planned reduction in headcount is an essential part of the measures taken by the Management Board to reduce costs and increase efficiency. The decision was taken against the background of aap's current economic situation and to adjust to the actual market and sales situation. The aim of the personnel measure is to streamline the Company's cost structure sustainably and thereby increase efficiency and flexibility. In this connection measures such as changing the stock market listing and discontinuing parts of the standard trauma portfolio have already been implemented in the financial year 2019.
 

aap develops innovative platform technologies and products in response to unmet needs and challenges in traumatology. With its three platform technologies LOQTEQ(R) (successfully on the market since 2011), antibacterial silver coating (in approval process) and resorbable magnesium implants (in development) the Company is addressing precisely these needs.
 

aap as a development-intensive company capitalizes not only self-produced assets but also expenditure on in-house and development projects (capitalized development costs) for which there is a high probability of approval and economically successful marketing. Development projects must be recognized as assets if all six criteria of IAS 38 "Intangible Assets" are met. All six criteria apply equally to each other. Among other things, the Company must prove the availability of technical, financial and other resources to complete the intangible asset. All capitalized development projects (developed in-house and acquired) must be subjected to an annual impairment test. Any resulting impairment loss is to be recognized immediately in the income statement in the year in which it occurs as an impairment loss.
 

In the financial year 2019 aap made substantial progress in its innovative key technologies antibacterial silver coating and resorbable magnesium implants. With regard to silver coating technology the Company received, among other things, approval to conduct a human clinical study by the Federal Institute for Drugs and Medical Devices ("BfArM") and a further funding commitment of up to around EUR 2.7 million from the Federal Ministry of Education and Research ("BMBF"). In the field of resorbable magnesium implant technology, aap was able to coordinate the regulatory approval path with the U.S. Food and Drug Administration (FDA) to the greatest possible extent and in a pilot animal study with the renowned Colorado State University recorded the first very promising results.
 

Irrespective of the progress made in financial year 2019 and the measures introduced to reduce costs and improve efficiency, the Company will, at least for the foreseeable future, be dependent on further financing through equity or debt measures. In addition, against the backdrop of the ever-increasing regulatory requirements (conversion to MDR), there are increasing uncertainties with regard to the duration of the approval process and, associated therewith, the risk of the timely financing of the projects under development. In order to take appropriate account of the above mentioned risks, aap has decided after a thorough analysis under the leadership of the new CEO to make an extraordinary value adjustment totaling EUR 10.8 million on the development projects antibacterial silver coating technology and resorbable magnesium implant technology in the course of preparing the annual and consolidated financial statements for 2019. This non-cash effect is shown below EBITDA as an extraordinary depreciation in the income statement 2019. Irrespective of this, the Management Board remains firmly convinced that the two innovative key technologies, antibacterial silver coating and resorbable magnesium implants, will be brought to market approval, particularly in cooperation with partners and with the help of the government grants already promised.
 

The progress mentioned above, especially in the financial year 2019, is being followed with great interest by various global orthopedic companies that have once again confirmed their interest in aap's innovative silver coating technology in talks currently underway. Specifically, the Company is discussing in addition to joint product development and approval projects also distribution partnerships as well as licensing deals up to the sale of the technology for specific application areas. In the area of the resorbable magnesium implant technology aap has intensified talks with technology-savvy investors in order to provide the financial basis for joint further development of the technology in a timely manner. With regard to its LOQTEQ(R) platform technology, aap is in well advanced discussions on the conclusion of a development and supply agreement with a worldwide leading U.S. medical technology company.
 

In parallel, the Management Board is currently evaluating various strategic alternatives for increasing value. These include, among other things, joint venture agreements up to corporate transactions (e.g. mergers, share or asset deals as well as carve-outs). These measures are being examined as part of the Company's ongoing holistic strategic planning and associated efforts to evaluate all available options for increasing the inherent value of aap's comprehensive trauma product portfolio and its various patented platform technologies.
 

Since individual decisions in the context of this forthcoming evaluation may have to be taken into account in the annual and consolidated financial statements for 2019, the Company has decided to postpone publication of the annual financial report 2019 (HGB) and the consolidated annual financial report 2019 (IFRS) until April 30, 2020. aap will comment again on any developments in this process after the Management Board has taken concrete decisions together with the Supervisory Board or has otherwise terminated the evaluation of the issues.

 

____________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The Company develops, manufactures and markets products for trauma. The IP-protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as the antibacterial silver coating technology and magnesium-based implants. These technologies address critical and unmet needs in trauma. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups, and hospital groups, while at international level it primarily uses a broad network of distributors in around 25 countries. In the US the Company pursues a hybrid distribution strategy with its subsidiary aap Implants Inc. Distribution is carried out both through distribution agents and partnerships with global orthopedic companies. aap Implantate AG's stock is listed in the General Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


For inquiries please contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Tel.: +49/(0)30/750 19 - 134; Fax.: +49/(0)30/750 19 - 290; f.franke@aap.de
 

16-March-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated August 13, 2019, 09:09 PM

aap Implantate AG adjusts outlook for financial year 2019

aap Implantate AG adjusts outlook for financial year 2019

aap Implantate AG / Key word(s): Change in Forecast/Profit Warning
aap Implantate AG adjusts outlook for financial year 2019

13-Aug-2019 / 21:09 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap") announces that after an in-depth analysis under the leadership of the new CEO, based on the available figures for the first six months of 2019, the plans for the second half of 2019 and the current status of ongoing discussions on planned strategic partnerships with global orthopaedic companies, the sales and EBITDA forecast for financial year 2019 is adjusted. In addition, one-time and non-cash depreciations on inventories and a change in the accounting treatment of instruments will burden the earnings in financial year 2019 below the EBITDA level.
 

aap registered sales of EUR 2.5 million (Q2/2018: EUR 2.7 million) in the second quarter of 2019 and thus a value at the lower end of the forecast. EBITDA in the second quarter of 2019 were burdened by significant one-time effects in a volume of about EUR 0.8 million and amounted to EUR -2.1 million (Q2/2018: EUR -1.5 million), thus being also at the lower end of the guidance. In contrast, aap increased sales on a half-yearly basis by +10% to EUR 6.0 million (H1/2018: EUR 5.4 million). Here, all regions contributed with positive growth rates (Germany +6%, North America +10 % and International +9%) to the realised increase in sales. EBITDA in the first six months of 2019 were EUR -3.1 million (H1/2018: EUR -3.1 million). Based on unchanged recurring EBITDA (adjusted by one-time effects) in the second quarter of 2019 of EUR -1.3 million, recurring EBITDA improved significantly on a half-yearly basis by +18% to EUR -2.2 million.
 

On the basis of the reported sales figures, the Management Board has examined in detail the expected business development in the second half of 2019 and subsequent quarters. The main focus here was on the long-term and sustainable sales development in contrast to short-term growth, possibly at the expense of margins. The result was that the sales growth in Germany, North America and International will not be realized to the extent originally planned for 2019 and therefore, despite the reported sales growth in the first six months of 2019, an adjustment of the full-year forecast is necessary.
 

The adjustment of EBITDA is the result of the sales development and planning described above and the analysis of the current status of ongoing discussions with a view to concluding planned strategic partnerships with global orthopaedic companies (distribution networks, product development and approval projects as well as licensing deals).
 

Against the background of these developments, aap adjusts its outlook for the financial year 2019 and now expects sales between EUR 11.0 million and EUR 13.0 million (previous forecast: EUR 13 million to EUR 15 million) and EBITDA of EUR -6.0 million and EUR -5.0 million (previous forecast: EUR -4.4 million and EUR -2.8 million). This corresponds to an increase in sales of 2% to 21% and an improvement in EBITDA of 6% to 22% compared with the previous year's figures.
 

In connection with the conversion of processes and documents to the regulatory requirements of the new EU Medical Device Regulation (MDR), current market requirements show that hospitals in the CE region are increasingly demanding sterile-packed implants. aap is currently working intensively on the documents for the conformity assessment procedure for CE marking and is striving to equip the first hospitals with sterile-packed products by the end of the year. In this context, non-sterile packaged products, which are in the customer's possession, will be replaced and taken back during this and the subsequent year. Current analyses show that it does not make economic sense to subject implants, especially those which are no longer in their original packaging, to extensive testing and, if necessary, revision. At the same time, the Management Board has decided that the accounting treatment and presentation of instruments will be changed at the end of the year. Previously, instruments were presented as part of inventories under current assets, since there was until recently a stronger focus on markets with distribution business, where the instruments were sold. In future, instruments will be presented as part of fixed assets and subject to scheduled depreciation over 3 years. This accounting treatment will lead to a more transparent delimitation of inventories as part of current assets and corresponds in its economic content more to the current focus on established markets as Germany, North America and Western Europe, where the instruments are provided and permanently handed over to the customer. In addition, aap recently announced that the Company will discontinue parts of its standard trauma business at the end of financial year 2019 and that the affected inventories of products are to be sold by the end of the current year. There is, however, the possibility that despite intensive efforts, it will not be possible to sell the entire inventory of products by the end of the year. aap will carry out a final evaluation of the valuation effects from the aforementioned measures as part of the preparation of the annual financial statements as at December 31, 2019. Initial preliminary calculations for the three issues show one-time and non-cash depreciations of up to EUR 4 million, which are reported as part of depreciation below EBITDA.
 

In response to the current development of sales and EBITDA, the Management Board will consistently continue its analysis to identify cost reduction and efficiency enhancement potentials. In this context, initial measures have already been implemented, such as the change of the stock exchange listing and the discontinuation of parts of the standard trauma portfolio. In addition, aap will in future focus even more on sales expansion with higher-margin customers and products, as well as on further driving forward the marketing of its innovative and promising technologies. With a view to its antibacterial silver coating technology, aap will further intensify talks and negotiations with interested global medical technology companies following the approval of the human clinical study by the Federal Institute for Drugs and Medical Devices ("BfArM"). For its innovative resorbable magnesium implant technology aap aims to push forward the further development of this promising technology jointly with partners under aap's management. All of these measures shall form the basis for sustainable and profitable growth.

 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de

13-Aug-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated August 08, 2019, 01:33 PM

aap Implantate AG receives BfArM approval for human clinical study for its antibacterial silver coating technology

aap Implantate AG receives BfArM approval for human clinical study for its antibacterial silver coating technology

aap Implantate AG / Key word(s): Study
aap Implantate AG receives BfArM approval for human clinical study for its antibacterial silver coating technology

08-Aug-2019 / 13:33 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap") announces that it has received the approval to conduct a human clinical study for its antibacterial silver coating technology by the Federal Institute for Drugs and Medical Devices ("BfArM") today. aap has thus reached a decisive milestone on the way to the targeted market approval.
 

With a view to the start of the human clinical study in Germany, aap now still needs the approval of the ethics commissions, which has already been applied for. In addition, the application for approval of the human clinical study in the US has been submitted at the Food and Drug Administration (FDA) at the beginning of August 2019.
 

The antibacterial silver coating technology developed by aap has, as a platform technology, a wide range of applications. Besides trauma, it can be used in further areas of orthopaedics as well as in cardiology, dentistry or for medical instruments, thus offering aap an enormous market potential. The developments in silver coating technology are pursued with keen interest by global medical technology companies which confirmed their interest in the innovative silver coating technology in continuous talks. In detail, the company discusses in addition to joint product development and approval projects also distribution partnerships as well as licensing deals up to the sale of the technology for specific application areas. Against the background of the approval of the human clinical study, aap will further intensify talks and negotiations with the global medical technology companies.
 

For further details, please refer to the press release published following this release.

 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


For inquiries please contact:

aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de
 

08-Aug-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated June 03, 2019, 10:15 AM

aap Implantate AG: Application for change within regulated market from Prime Standard to General Standard

aap Implantate AG: Application for change within regulated market from Prime Standard to General Standard

aap Implantate AG / Key word(s): Miscellaneous
aap Implantate AG: Application for change within regulated market from Prime Standard to General Standard

03-Jun-2019 / 10:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Management Board of aap Implantate AG resolved on 3 June 2019 with the approval of the Supervisory Board of the same day on a change of the stock exchange listing from the Prime Standard to the General Standard of the regulated market of the Frankfurt Stock Exchange. On this basis aap will now promptly apply to the management board of the Frankfurt Stock Exchange for the revocation of admission of the aap shares to the sub-segment of the regulated market with additional obligations arising from the admission (Prime Standard) pursuant to § 57 of the stock exchange regulations of the Frankfurt Stock Exchange, whereby the aap shares will be listed on the regulated market (General Standard) for trading ex officio.
 

By changing the stock exchange segment aap's post-listing obligations, as certain reporting and publication requirements, will omit. This step enables the company to reduce the costs of the stock exchange listing and to use existing resources more efficiently and purposefully. aap will comply with the high transparency requirements of the regulated market in the General Standard in the future as well. At the same time, investors of the company will continue to have an unrestricted trading opportunity for their aap shares in the regulated market of the Frankfurt Stock Exchange.
 

The revocation of the admission will become effective upon the expiration of a period of three months after the publication of the revocation decision by the management board of the Frankfurt Stock Exchange on the internet(www.deutsche-boerse.com).


 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de


03-Jun-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated April 17, 2019, 10:15 AM

aap Implantate AG resolves on capital increase with subscription rights

aap Implantate AG resolves on capital increase with subscription rights

aap Implantate AG / Key word(s): Capital Increase/Financing
aap Implantate AG resolves on capital increase with subscription rights

17-Apr-2019 / 10:15 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The information contained in this announcement is not intended for publication or distribution in or within the United States of America, Australia, Canada or Japan.

 

The Management Board of aap Implantate AG resolved on 17 April 2019 with the approval of the Supervisory Board of the same day on a capital increase against cash contributions out of the authorized capital 2014/I with subscription and oversubscription rights of the shareholders of the company. aap Implantate AG's share capital shall be increased by up to EUR 4,784,485.00 by issuing up to 4,784,485 new no-par value bearer shares from the current amount of EUR 28,706,910.00 to up to EUR 33,491,395.00. The new shares shall be offered to the shareholders of the company at a subscription price of EUR 1.04 per new share based on a subscription ratio of 6:1. The new shares are entitled to participate in dividends as of 1 January 2018.
 

At this time, aap Implantate AG has commitments from its shareholders to exercise subscription and oversubscription rights in a volume of EUR 2.3 million in total. This corresponds to approx. 46% of the capital increase.
 

The capital increase with subscription rights is part of a package of measures aap Implantate AG will implement at short notice to strengthen its financial base. In this context, the net proceeds from the transaction shall be inter alia used to finance the company's planned sales growth and to prepare and conduct a human clinical study for its silver coating technology.
 

The new shares will be offered to the shareholders of aap Implantate AG for subscription in an indirect subscription offer during a subscription period. The subscription period is expected to start on 25 April 2019 (00.00 hours CET) and to end on 9 May 2019 (24.00 hours CET). No trading of subscription rights will be organized and subscription rights which are not exercised will expire worthless. In addition to exercising their subscription rights, all shareholders of the company have the option to participate in the capital increase within an oversubscription. These oversubscription rights must also be exercised during the subscription period. New shares, which are not subscribed as part of the subscription offer, shall be offered to qualified institutional investors for sale by means of a private placement at a price at least equaling the subscription price.
 

The capital increase with subscription rights is accompanied by M.M.Warburg & CO (AG & Co.) KGaA. For further details regarding the transaction please refer to the subscription offer, which will be published before the start of the subscription period on the corporate website of the company (www.aap.de) in the section "Investors / Capital Increase" as well as in the Federal Gazette under www.bundesanzeiger.de.

 

This announcement constitutes neither an offer nor a solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan or any other jurisdiction in which an offer is unlawful.

This announcement is not an offer of securities for sale in the United States. Securities may be offered or sold in the United States only upon prior registration or upon exemption from the obligation of prior registration pursuant to the Securities Act. If a public offering of securities were to take place in the United States, it would be effected by means of a securities prospectus which investors could obtain from the Company. This prospectus would contain detailed information about the Company and its management, as well as financial information. There will be no public offering of the securities referred to in this announcement in the United States.

Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to or for the account of persons resident in Australia, Canada or Japan.

 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


For inquiries please contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de


17-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated April 15, 2019, 02:25 PM

aap: Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019

aap: Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019

aap Implantate AG / Key word(s): Personnel
aap: Chairman of the Management Board / CEO Bruke Seyoum Alemu to retire early as of 30 April 2019; Rubino Di Girolamo appointed as successor as of 1 May 2019

15-Apr-2019 / 14:25 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Supervisory Board of aap Implantate AG ("aap") and the Chairman of the Management Board / CEO, Bruke Seyoum Alemu (54), today agreed on an early termination of his term of office as of 30 April 2019. Bruke Seyoum Alemu thereupon resigned his mandate as Member and Chairman of the Management Board / CEO of aap by mutual agreement with the Supervisory Board with effect as of 30 April 2019 and will retire from the Management Board at this time. Mr. Alemu continues to be in charge of aap's operations as Chairman of the Management Board / CEO up to this time. Mr. Alemu will support the company on a consulting basis after his retirement from the Management Board.
 

Also with today's resolution, the Supervisory Board of the company appointed Mr. Rubino Di Girolamo (57), currently Member of the Supervisory Board at aap, as new Chairman of the Management Board / CEO of aap with effect as of 1 May 2019.


 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


For inquiries please contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de

15-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated April 02, 2019, 12:03 PM

aap Implantate AG: Sales in Q1/2019 with EUR 3.5 million by EUR 0.5 million above the guidance

aap Implantate AG: Sales in Q1/2019 with EUR 3.5 million by EUR 0.5 million above the guidance

aap Implantate AG / Key word(s): Preliminary Results/Development of Sales
aap Implantate AG: Sales in Q1/2019 with EUR 3.5 million by EUR 0.5 million above the guidance

02-Apr-2019 / 12:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap") announces that based on first preliminary evaluations sales in the first quarter of 2019 amount to about EUR 3.5 million, thus exceeding the guidance communicated in January 2019 (Sales Q1/2019: EUR 2.0 million to EUR 3.0 million) by around EUR 0.5 million or about 17%. Against the background of this development the Management Board now anticipates EBITDA of EUR -1.2 million to EUR -0.9 million (previous: EUR -1.8 million to EUR -1.2 million) for the first quarter of 2019.
 

For the entire year 2019 the Management Board continues to maintain its initial guidance for sales between EUR 13.0 million and EUR 15.0 million and EBITDA between EUR -4.4 million and EUR -2.8 million.
 

For further details reference is made to the press release published subsequently to this release.


 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
 


Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de

02-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated November 02, 2018, 06:32 PM

aap Implantate AG adjusts outlook for financial year 2018

aap Implantate AG adjusts outlook for financial year 2018

aap Implantate AG / Key word(s): Change in Forecast/Profit Warning
aap Implantate AG adjusts outlook for financial year 2018

02-Nov-2018 / 18:32 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap") announces that based on the figures available for the first nine months of 2018 and its plans for the fourth quarter of 2018 as well as due to one-time costs in connection with the step-up strategy implementation it is adjusting its sales and EBITDA forecast for financial year 2018.
 

According to preliminary figures, total sales in the third quarter of 2018 and in the nine-month period increased on the same periods in the previous year to EUR 2.7 million (Q3/2017: EUR 2.6 million) and EUR 8.2 million (9M/2017: EUR 8.0 million) respectively, while trauma sales grew by 7% to EUR 2.8 million and by 6% to EUR 8.2 million respectively. EBITDA in the third quarter of 2018 stood at EUR -1.5 million and for the first nine months at EUR -4.6 million. Both key figures, sales and EBITDA, were therefore in the third quarter of 2018 within the forecast published in August.
 

Despite the reported growth so far an adjustment of the forecast for the full year is necessary. The background is primarily the sales development in North America falling short of expectations. Regarding aap's activities in this region, the company could not sign further contracts with global partners in the current financial year and distribution business was temporarily burdened by the loss of certain distributors. This shortfall in sales could not be offset on a short-term basis elsewhere. In contrast, aap reports for the nine-month period of 2018 a positive development with double-digit growth rates both in Germany (+12% to EUR 2.1 million) and in its international business (+28% to EUR 4.5 million).
 

EBITDA adjustment is a consequence of the above-mentioned sales development and one-time costs for strategic measures. These non-recurring out of budget expenses for the step-up strategy implementation to develop aap into a sustainably growing pure player in trauma, will burden EBITDA in the fourth quarter and subsequent months.
 

Against the background of these developments aap is adjusting its outlook for the financial year 2018 and now anticipates sales between EUR 10.0 million and EUR 11.7 million (previous forecast: EUR 13 million to EUR 15 million) and EBITDA of EUR -6.9 million and EUR -5.9 million (previous forecast: EUR -5 million and EUR -3.4 million).
 

In response to the current development of the distribution business in North America the company has strengthened its sales team. In addition, aap has in recent months already signed 12 new contracts with distributors that should be reflected in corresponding sales dynamics in coming quarters. Furthermore, aap is currently in talks with global partners on some projects whereby the realization is likely expected to be shifted to financial year 2019.
 

The figures contained in this release for the third quarter of 2018 and the first nine months are preliminary and subject to change until final publication. aap plans to publish the final figures for the third quarter of 2018 and the first nine months on 14 November 2018 in a quarterly statement.
 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.



For inquiries please contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin
Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de


02-Nov-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated July 19, 2017, 10:23 AM

aap Implantate AG: Resolution on a Capital Reduction

aap Implantate AG: Resolution on a Capital Reduction

aap Implantate AG / Key word(s): Corporate Action/Miscellaneous

19-Jul-2017 / 10:23 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Management Board of aap Implantate AG resolved on 19 July 2017 with the approval of the Supervisory Board of the same day to redeem the 2,249,746 no-par value shares bought by means of the voluntary public share buyback offer of aap Implantate AG and to reduce the company's share capital by the corresponding amount of EUR 2,249,746.00. The redemption and capital reduction take place without a further resolution of the Annual General Meeting by exercising the authorization of the Annual General Meeting of 13 June 2014. After the implementation of the capital reduction aap Implantate AG's share capital amounts to EUR 28,582,410.00 and is divided into 28,582,410 no-par value ordinary bearer shares in a proportional amount of EUR 1.00 per no-par value share of the share capital.

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


Contact:

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de


19-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated July 12, 2017, 08:01 PM

aap Implantate AG: Result of Public Share Buyback Offer

aap Implantate AG: Result of Public Share Buyback Offer

aap Implantate AG / Key word(s): Share Buyback/Corporate Action

12-Jul-2017 / 20:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG announces that a total of 3,906,681 no-par value bearer shares of the company were offered for repurchase to the company within the acceptance period of the voluntary public share buyback offer from 20 June 2017, 00.00 hours (CEST) until 10 July 2017, 24.00 hours (CEST). Thereby the share buyback offer of aap Implantate AG was oversubscribed. The shareholders' declarations of acceptance are therefore taken into account proportionally in accordance with Section 3.3 of the offer document.

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
 


Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de

12-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated June 15, 2017, 10:54 AM

aap Implantate AG: Public Share Buyback Offer

aap Implantate AG: Public Share Buyback Offer

aap Implantate AG / Key word(s): Share Buyback/Corporate Action

15-Jun-2017 / 10:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The Management Board of aap Implantate AG resolved on 15 June 2017 with the approval of the Supervisory Board of the same day to purchase up to 2.25 million no-par value bearer shares of the company by means of a voluntary public share buyback offer against a cash payment of EUR 1.52 per no-par value share for a maximum total purchase price (including incidental costs) of up to EUR 3.5 million. The shares offered for purchase correspond to a proportion of up to approximately 7.3% of the company's current share capital. With the public share buyback offer the Management Board makes use of the authorization granted by the Annual General Meeting resolution of 13 June 2014 to acquire treasury shares. With this measure aap Implantate AG implements the announced partial distribution of proceeds from last year's sale of the subsidiary aap Biomaterials GmbH to shareholders.

The shares which are acquired as a result of the public share buyback offer can be used for all purposes permitted by law. The Management Board intends to redeem the shares acquired by means of the public share buyback offer.

The acceptance period starts on Tuesday, 20 June 2017, 00.00 hours (CEST) and ends on Monday, 10 July 2017, 24.00 hours (CEST). The offer document will be published before the start of the acceptance period on the corporate website of the company (www.aap.de) in the section "Investors / Share Buyback" as well as in the Federal Gazette under www.bundesanzeiger.de.

 

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
 


Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de

15-Jun-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated May 08, 2017, 10:27 AM

aap Implantate AG: Management Board and Supervisory Board plan share buyback to partially distribute proceeds from the sale of aap Biomaterials GmbH

aap Implantate AG: Management Board and Supervisory Board plan share buyback to partially distribute proceeds from the sale of aap Biomaterials GmbH

aap Implantate AG / Key word(s): Share Buyback/Corporate Action

08-May-2017 / 10:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


In connection with the resolution on their proposals to the ordinary annual general meeting of the company Management Board and Supervisory Board of aap Implantate AG decided today to implement a share buyback within the next months in order to partially distribute proceeds from last year's sale of the subsidiary aap Biomaterials GmbH to shareholders as announced. Based on the current share price level of the aap share it is intended within the share buyback to purchase up to 2.4 million shares of the company from the shareholders for a maximum total purchase price (including incidental costs) of up to EUR 3.5 million. The further details of the share buyback, including the purchase price, will be determined and published by the Management Board with the consent of the Supervisory Board within the next weeks. If market circumstances or the share price development changes the Management Board reserves the right to adapt the conditions of the intended share buyback or refrain from it. Against the background of the intended share buyback Management Board and Supervisory Board will neither propose a dividend payment nor a capital decrease to the annual general meeting taking place on 16 June 2017 - both measures have been taken into consideration for the partial distribution of proceeds from the sale of aap Biomaterials GmbH as well. The proposals from Management Board and Supervisory Board to the annual general meeting will be published together with the convention on 10 May 2017 in the Federal Gazette.

---

Contact:

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.


08-May-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated March 21, 2017, 02:57 PM

aap Implantate AG: Sales by KEUR 514 and EBITDA by KEUR 450 slightly below guidance for financial year 2016 due to failure of distributor to fulfil contractual duties

aap Implantate AG: Sales by KEUR 514 and EBITDA by KEUR 450 slightly below guidance for financial year 2016 due to failure of distributor to fulfil contractual duties

aap Implantate AG / Key word(s): Profit Warning/Final Results

21-March-2017 / 14:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


aap Implantate AG ("aap") announces that in course of drawing up the annual financial statements for 2016 the Management Board decided as a precautionary measure to revoke an initial sale with a distribution partner invoiced in the financial year. The reason is a delayed payment of the contractual due purchase price. Rescission of the initial business results in a reduction in sales in the financial year 2016 by KEUR 757. In the continued operation in financial year 2016 sales are at EUR 10.5 million and EBITDA at EUR -7.9 million and thereby slightly below the current guidance.


Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de

21-March-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this
Insider Information according to Article 17 MAR dated December 15, 2016, 10:38 AM

aap Implantate AG: aap updates forecast for financial year 2016 due to delays in sales development in various markets

aap Implantate AG: aap updates forecast for financial year 2016 due to delays in sales development in various markets

aap Implantate AG / Key word(s): Change in Forecast/Profit Warning 15-Dec-2016 / 10:38 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap Implantate AG ("aap") announces that it will not achieve the previous sales and EBITDA forecast for financial year 2016 for the continued operation. The reasons for this adjustment are delays in the sales development in various markets leading to a sales shift in financial year 2017. Against the background of these developments aap adjusts its forecast for financial year 2016 for the continued operation and now anticipates sales between EUR 11.0 million and EUR 12.1 million as well as an EBITDA of EUR -7.5 million to EUR -7.0 million. For the EBITDA of the group (continued and discontinued operation including deconsolidation profit from the sale of aap Biomaterials GmbH) the company anticipates a value of between EUR 16.5 million and EUR 17.0 million. As already reported, EBITDA in financial year 2016 was additionally burdened by one-time effects of different measures totaling EUR 0.6 million. In detail this is a special effect of the premature termination of a long-term LOQTEQ(R) license agreement (EUR 0.3 million) as well as one- time costs of implemented personnel measures (EUR 0.3 million). Both measures will result in noticeable cost savings and thereby earnings improvements of the company in the years to come. With a view to the sales development in financial year 2016 an ambivalent picture appears which was significantly impacted by two opposite effects. On the one hand, China, which was despite halted growth a main sales market in 2015, could not make a contribution towards sales in financial year 2016 (Sales FY/2015: about EUR 3.3 million). The negotiations about a continuation of the distribution business have recently been concluded and the cooperation will continue in 2017. As a consequence the business in China will recover in the next year. On the other hand, aap achieved substantial progress in connection with the aimed focus on established markets such as North America and Europe in the year to date. The share of sales attributable to North America and Europe increased in the nine-month period 2016 compared to the corresponding period in the previous year by about 50% to EUR 5.1 million (9M/2015: EUR 3.4 million). Overall, the realized pleasing sales increases in North America and Europe in financial year 2016 could however not compensate the missing sales contributions from China. The Management Board currently sees in both markets a dynamic development which is expected to continue in the coming months. North America and Europe will stay the main growth drivers for the planned sales development in financial year 2017 as well. In the area of silver coating technology, aap has made progress in the ongoing CE conformity assessment procedure in financial year 2016 as well, and continues an intensive and constructive exchange with the notified body. Simultaneously, the company is preparing the required documents for an approval by the US Food and Drug Administration (FDA). On the basis of the previous findings and the anticipated future developments the Management Board aims at a CE approval and the closing of a license deal in financial year 2017 which will have visible influence on financial figures. Contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de --------------------------------------------------------------------------- 15-Dec-2016 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service
Insider Information according to Article 17 MAR dated August 10, 2016, 09:42 AM

aap Implantate AG: Deconsolidation profit from the sale of aap Biomaterials GmbH leads to an increase of 2016 EBITDA forecast for the group

aap Implantate AG: Deconsolidation profit from the sale of aap Biomaterials GmbH leads to an increase of 2016 EBITDA forecast for the group

aap Implantate AG / Key word(s): Change in Forecast/Final Results 10.08.2016 09:42 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - Adjustment of 2016 EBITDA forecast for continued operation due to technical IFRS reporting requirements - aap Implantate AG ("aap") signed a notarized share purchase agreement on 22 March 2016 with Keensight Capital for the sale of 100% of the company shares in its subsidiary aap Biomaterials GmbH. The transaction was closed on 11 May 2016. On the basis of the audited interim financial statements of aap Biomaterials GmbH as at 11 May 2016 and the subsequent audit review of the resulting effects in aap's consolidated interim financial statements as at 30 June 2016, there arises, besides the assets and liabilities disposed of and recognized in the deconsolidation profit so far, an additional earnings-increasing effect from the assumption and disposal of intra-group liabilities of aap Biomaterials GmbH by the purchaser of EUR 3.7 million. That leads to a deconsolidation profit of EUR 23.3 million in aap's consolidated interim financial statements as at 30 June 2016 that is stated in the discontinued operation. Due to the sale of aap Biomaterials GmbH at the end of March 2016, the company is stated as a so called discontinued operation according to IFRS 5. Contrary to previously published interim financial statements, a clarification of the relevant reporting standard published at the end of 2015 requires transactions between affiliated group companies to be stated differently. This change in presentation leads to the fact that economic and legal services provided by the continued operation totalling EUR 0.4 million have to be presented consolidated. As a result these services are not being stated as income of the continued operation and at the same time are not being shown as expenses of the discontinued operation as well. Overall, this change in treatment leads to a shift in EBITDA from the continued to the discontinued operation. Both effects mentioned before result in an EUR 4.1 million increase in EBITDA of the discontinued operation as at 30 June 2016 to a total of around EUR 24 million. As a result, aap adjusts its EBITDA forecast for the financial year 2016 as follows: - EBITDA of the continued operation of between EUR -5.9 million and EUR -4.3 million (previously between EUR -5.5 million and EUR -3.9 million) due to technical IFRS reporting requirements for the continued and the discontinued operation - EBITDA of the group (continued and discontinued operation including deconsolidation profit from the sale of aap Biomaterials GmbH) of between EUR 18.1 million and EUR 19.7 million (previously between EUR 14.1 million and EUR 15.7 million). aap plans to publish the final results for the second quarter respectively the first half of financial year 2016 on 12 August 2016. Contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de 10.08.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated April 22, 2016, 05:35 PM

aap Implantate AG: Annual financial statements 2015: Sales at EUR 28 million within the guidance and EBITDA KEUR 400 below the forecast

aap Implantate AG: Annual financial statements 2015: Sales at EUR 28 million within the guidance and EBITDA KEUR 400 below the forecast

aap Implantate AG / Key word(s): Profit Warning/Final Results 22.04.2016 17:35 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - EBITDA 2015 burdened by one-time value adjustment on inventories (KEUR 700) due to portfolio streamlining and potential cannibalization effects - aap Implantate AG ("aap") recently signed a purchase agreement for the sale of all shares in its subsidiary aap Biomaterials GmbH and is currently working on the fulfillment of the conditions precedent in order to close the transaction. Upon closing of the transaction, aap becomes a pure player in trauma with a portfolio of IP-protected innovative technologies. Against this background and after an extensive feedback from customers in the first quarter of 2016 as well as due to the substantial expansion of the LOQTEQ(R) portfolio in the 2015 financial year, a cannibalization of standard trauma products by LOQTEQ(R) products may occur in future. In course of the focusing on the trauma business aap intends to sell the remaining 33% share in aap Joints GmbH (Recon products for knee, hip and shoulder) in 2016 and to discontinue its supplier activities in this non-core area. In order to adequately address the potential future sales risk for standard trauma products, and to take into account the decision in the context of aap Joints GmbH, the Management Board made in course of preparing the consolidated and annual financial statements 2015 an extraordinary and one-time value adjustment on inventories of standard trauma and recon products in the amount of KEUR 700. This value adjustment leads to a reduction in EBITDA in the 2015 financial year to the same extent. As a result, the EBITDA in the 2015 financial year amounts to EUR -1.9 million and is therefore KEUR 400 below the forecast made in November 2015 of EUR -1.5 million to EUR 1.0 million. The sales in the 2015 financial year amount to EUR 28.0 million and are therefore within the guidance of EUR 27.5 million and EUR 31.5 million. Contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de 22.04.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated March 22, 2016, 02:21 AM

aap Implantate AG: aap sells biomaterials business for EUR 36 million and becomes a pure player in trauma with innovative technologies

aap Implantate AG: aap sells biomaterials business for EUR 36 million and becomes a pure player in trauma with innovative technologies

aap Implantate AG / Key word(s): Disposal/Change in Forecast 22.03.2016 02:21 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc-Announcement according to § 15 WpHG aap sells biomaterials business for EUR 36 million and becomes a pure player in trauma with innovative technologies - Closing of the transaction will lead to adjustment of 2016 guidance; Postponement of publication of consolidated and annual financial statements 2015 - Berlin, 22 March 2016 aap Implantate AG ("aap") signed a notarized share purchase agreement today with a leading European private equity firm for the sale of 100% of the company shares in its subsidiary aap Biomaterials GmbH, which has its registered office in Dieburg. The purchase price is based on an assumed enterprise value of aap Biomaterials GmbH of EUR 36 million and will be due for payment after closing of the transaction. The closing of the transaction is subject to the market standard conditions precedent, which are to be met within the next three months. Upon closing of the transaction, the existing profit and loss transfer agreement between aap and aap Biomaterials GmbH will be terminated. The operation sold within the transaction (discontinued operation) consists of aap Biomaterials GmbH, which is specialized in the development, production and marketing of bone cements, mixing systems and related accessories, and aap's distribution business in this area. In 2015, the operation sold recorded sales based on preliminary figures amounting to EUR 16.0 million. The closing of the transaction will result in a positive one-time deconsolidation effect on the earnings level. The company plans to use part of the proceeds to finance further growth and to distribute part of them to its shareholders. The complete consolidated and annual financial statements as of 31 December 2015 of aap will be published by 29 April 2016 the latest. The reason for the delay in the publication is the sale of aap Biomaterials GmbH, which must already be stated as a so-called discontinued operation in the consolidated financial statements for 2015. This leads to extensive reporting requirements in the notes and the management report as well as in various presentations of results in the consolidated financial statements. Upon closing of the transaction, aap's previous sales and EBITDA forecast for the 2016 financial year will be no longer valid. The company will publish a new and updated guidance for the current financial year after closing. In this context, aap aims to announce also further details regarding the use of a part of the proceeds for the benefit of the shareholders. The closing of the transaction is the last step in the transformation of aap from a general medtech company to a pure player in trauma. Contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de 22.03.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated November 02, 2015, 09:47 PM

aap updates forecast for financial year 2015 due to delays in sales development in strategic trauma markets and in project deals in the biomaterials business

				
					

aap updates forecast for financial year 2015 due to delays in sales development in strategic trauma markets and in project deals in the biomaterials business

aap Implantate AG / Key word(s): Change in Forecast/Profit Warning 02.11.2015 21:47 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap Implantate AG (XETRA: AAQ.DE) announces that it will not achieve the sales and EBITDA targets it has forecasted for financial year 2015. The reasons for this adjustment are mainly delays in trauma sales development in a number of strategic growth markets (China, Russia and Turkey) due to deteriorated economic framework conditions and in the US market entry due to protracted administrative processes in hospitals as well as uncertainties in respect of product approval in Brazil. Furthermore, as a result of mergers and acquisitions in the global orthopaedic industry and the related priorities set by decision makers, delays have occurred in concluding pending project deals in the biomaterials business. Against the background of these developments aap Implantate AG adjusts its forecast for financial year 2015 and now anticipates sales between EUR 27.5 million and EUR 31.5 million and an EBITDA of EUR -1.5 million to EUR 1.0 million. In respect of the outlook for the upcoming financial year and beyond, the Management Board is nonetheless convinced that with the sales activities already under way in the United States and Europe the growth story with a 5-year CAGR of 20% in the trauma business is intact. The growth drivers are the LOQTEQ(R) product portfolio and the silver coating technology. In addition, the company is intensifying the already existing measures to improve profitability and efficiency. From 2016 on, the US will become one of the core markets in the company's growth strategy. In this strategic market aap Implantate AG has already carried out first procedures with its LOQTEQ(R) products in various hospitals and has generated first sales. In the silver coating technology area the company has achieved substantial progress in the course of the financial year. It includes to a large extent the accomplishment of extensive animal studies, that are an important basis for product approval. On the basis of the current state of development and subject to the results of current consultations with the approval authorities the company still plans to submit its CE approval application this financial year. The approval process with the US Food and Drug Administration (FDA) is expected to be launched subsequently. The transformation of aap Implantate AG into a focused trauma company remains a core objective of our strategic direction. In January 2016 we will provide in a separate release an initial outlook for the financial year 2016 and the first quarter of 2016. Contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; f.franke@aap.de 02.11.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated October 27, 2014, 07:48 PM

aap Implantate AG updates outlook for 2014

				
					

aap Implantate AG updates outlook for 2014

aap Implantate AG / Key word(s): Change in Forecast/Profit Warning 27.10.2014 19:48 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap updates outlook in view of possible delays in product approvals, U.S. market entry and project deals aap Implantate AG announces that possible delays in product approvals and registrations in Latin America, in gaining U.S. market entry for our LOQTEQ(R) and trauma product portfolio, and in ongoing project deals may negatively impact our sales and EBITDA forecast for 2014. The Management assumes that sales losses directly attributable to the disposal of equity in the dental joint venture aap BM productions GmbH in the second quarter of 2014 totaling EUR 1.0 million cannot be compensated by sales in other business areas. Based on the previous sales forecast for the fiscal year 2014 of approx. EUR 35 million and taking into account the aforementioned effect original sales goal amounts to EUR 34 million. In view of these uncertainties we see for 2014 a target corridor between EUR 30 million and EUR 34 million for full-year sales and between EUR 2.0 million and EUR 4.5 million for full-year EBITDA (previous forecast: between EUR 5.0 million and EUR 6.0 million). The strategic focus of transforming aap Implantate AG into a leading European trauma enterprise remains our highest priority. Contact: aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; m.heydrich@aap.de 27.10.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated April 28, 2014, 11:07 PM

Changeover at aap Implantate AG: Bruke Seyoum Alemu appointed as new CEO

				
					

Changeover at aap Implantate AG: Bruke Seyoum Alemu appointed as new CEO

aap Implantate AG / Key word(s): Change of Personnel/Agreement 28.04.2014 23:07 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ongoing transformation to a leading trauma company keeping management continuity aap Implantate AG announces that its Supervisory Board named Bruke Seyoum Alemu, 48, Chief Operating Officer of aap Implantate AG since 2008, as the company's new chairman of the Management Board and Chief Executive Officer (CEO), effective as of June 1, 2014. With today's successful completion of the sale of aap's Dutch subsidiary EMCM B.V., which is a consistent step in the strategy implementation towards a focused trauma company, the Supervisory Board in consultation with the Management Board has agreed to reduce the size of aap's Management Board from three to two members. In view of the above, current CEO Biense Visser and the Supervisory Board have agreed to terminate Mr. Visser's Management Board contract prematurely as of May 31st, 2014. To maintain continuity, Mr. Visser is prepared to serve on aap Implantate AG's Supervisory Board provided that the necessary legal requirements are fulfilled. The company assumes that its majority shareholders will support Mr. Visser's move to the Supervisory Board and nominate him accordingly on the occasion of the upcoming annual shareholders meeting. In a separate press release aap will report in detail regarding this change. __________________________________________________________________________ ________________ aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets - About aap Implantate AG aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play. Forward-looking statement This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de 28.04.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated February 24, 2014, 05:30 PM

aap Implantate AG divests its contract manufacturing business for EUR 18 million cash to private Equity company

				
					

aap Implantate AG divests its contract manufacturing business for EUR 18 million cash to private Equity company

aap Implantate AG / Key word(s): Strategic Company Decision/Disposal 24.02.2014 17:30 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap Implantate AG (XETRA: AAQ.DE) announced today a definitive agreement under which a Private Equity Company will acquire its contract manufacturing business that is concentrated in its subsidiary, European Medical Contract Manufacturing B.V. (EMCM). The purchase price for all shares in EMCM is EUR 18 million and payable in cash under a deferred payment schedule. The cash consideration will flow to aap in three installments until end of April 2014. Closing (notarial attestation) is expected to occur within the next days. EMCM develops and manufactures sterile medicinal products for the Biomaterials, Pharmaceuticals and Tissue Engineering markets and achieved revenues of EUR 12 million in 2013. The transaction will result in a one-time non-cash deconsolidation effect of approx. EUR 4.0 million to EUR 4.5 million. In the process, the company decided to adjust its capitalization policy for its Biomaterials activities and to stop all respective development projects. This will result in a one-time non-cash extraordinary depreciation of capitalized development costs of approx. EUR 2.3 million. The mentioned effects will be accounted for in the consolidated financial statements for 2013 and will affect the EBIT. The contract manufacturing business will be presented as a discontinued operation in aap's consolidated financial statements for 2013. The transaction supports the Company's strategy to focus on its high growth Trauma and bone cement business. The proceeds will be used for accelerating the development of further LOQTEQ(R), silver coated and magnesium trauma products. Furthermore, aap will start evaluating strategic acquisition opportunities that support the trauma growth strategy. aap will comment the transaction in more detail and elaborate more on the financial impact in a separate press release. ________________________________________________________________________ aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets - About aap Implantate AG aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play. Forward-looking statement This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: m.heydrich@aap.de 24.02.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated June 28, 2013, 12:32 PM

aap Implantate AG: Private Equity partner acquires 67% of aap's subsidiary for Orthopaedic products for the Asian market

				
					

aap Implantate AG: Private Equity partner acquires 67% of aap's subsidiary for Orthopaedic products for the Asian market

aap Implantate AG / Key word(s): Joint Venture/Contract 28.06.2013 12:32 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap Implantate AG (XETRA: AAQ.DE) and a British Virgin Island-based Private Equity Company ('PE Company') announced today that they have entered a joint venture for aap's reconstructive implant business in the greater Asian market. Under the terms of the agreement, the PE Company will acquire 67% of the shares of aap's reconstructive implant subsidiary, aap Joints GmbH, for a consideration of EUR 3 million in cash, subject to adjustments for working capital. The notary authorization of all agreements is scheduled July 3rd. aap Joints GmbH focuses on reconstructive implants (hips, knees, shoulder) and related products, including the bone cement brand C-ment(R). In 2012 aap Joints GmbH recorded sales of EUR 2.2 million. Outside of the greater Asian market, aap Joints GmbH will continue to serve its existing customer base in Europe and the Middle East. aap Implantate AG will update its guidance for the third quarter and the full year 2013 to include the impact of the joint venture in conjunction with the publication of the report for the second quarter on August 14, 2013. This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. ____ ______________________________________________________ aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets - aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play. For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, m.heydrich@aap.de 28.06.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated April 03, 2013, 01:31 PM

aap Implantate AG: Increased EBITDA-Forecast for Q1 to EUR 3.1 million

				
					

aap Implantate AG: Increased EBITDA-Forecast for Q1 to EUR 3.1 million

aap Implantate AG / Key word(s): Quarter Results 03.04.2013 13:31 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Preliminary figures show that aap Implantate AG (XETRA: AAQ.DE) increased the EBITDA in the first quarter of the financial year 2013 to around EUR 3.1 million, up by 48% on the previous year's EUR 2.1 million, while sales totalling around EUR 10.4 million (previous year: EUR 9.9 million). Its previous EBITDA forecast was between EUR 1.5 million and EUR 1.9 million. The EBITDA increase was due to the favourable development of achieving milestones sooner than expected. For the full financial year 2013, the Management Board reaffirms for now its sales growth forecast of at least 10% to around EUR 40.0 million and its EBITDA growth forecast of at least 15% to over EUR 7.0 million. As already noted in the consolidated financial statements, quarterly fluctuations in growth and profitability are to be expected in view of the product and project sales mix. Publication of the interim report for the first quarter of 2013 is scheduled for 15 May 2013. This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. Contact: Contact: aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; m.heydrich@aap.de 03.04.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated March 29, 2013, 07:12 PM

aap Implantate AG: Closing of a development and supply agreement supports positive outlook for 2013

				
					

aap Implantate AG: Closing of a development and supply agreement supports positive outlook for 2013

aap Implantate AG / Key word(s): Contract 29.03.2013 19:12 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap Implantate AG (XETRA: AAQ.DE) today closed an in the second quarter of 2012 signed development and supply agreement with a global medtech company. The effectiveness of the agreement was depended on the achievement of various conditions precedent, which came into effect today. The contract relates to the development of a biomaterial and its mixing and application device followed by the transfer of the know-how. When all of the milestones of the development agreement are reached, aap will receive payments totalling EUR 6.9 million (based on current exchange rates). The following milestone payments will be booked in the first quarter of 2013: a EUR 2.8 million upfront-payment is to be presented as 'other operating income', two other milestone payments totalling EUR 1.5 million will be accounted for as 'sales'. The supply agreement has a term of 24 months with an option for renewal. At least EUR 1.4 million in sales arising from the supply agreement is anticipated in 2013. The conclusion of the development and supply agreement supports our positive outlook for 2013. For now, we reaffirm our forecast for 2013: Sales and EBITDA growth to be at least 10% and 15% respectively. This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. Contact: Contact: aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; m.heydrich@aap.de 29.03.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated October 01, 2012, 04:04 PM

aap Implantate AG: 25% revenue growth to EUR 8.6 million in the third quarter of 2012; Total sales in the first nine months of 2012 increase to EUR 27.5 million (+31%)

				
					

aap Implantate AG: 25% revenue growth to EUR 8.6 million in the third quarter of 2012; Total sales in the first nine months of 2012 increase to EUR 27.5 million (+31%)

aap Implantate AG / Key word(s): Quarter Results/Preliminary Results 01.10.2012 16:04 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE), a global medical device company focused on innovative trauma products and biomaterials for the orthopaedic market, achieved sales in the third quarter of 2012 of EUR 8.6 million, a 25% increase on the previous year's figure of EUR 6.9 million. Therefore, total sales in the first nine months of the financial year 2012 increase by 31% to EUR 27.5 million (previous year: EUR 21 million). The sales growth in the third quarter 2012 was mainly driven by increased sales with our innovative LOQTEQ(R) product family as well by a sales increase in the Biomaterials business. In the third quarter of 2012 we signed distribution agreements for our LOQTEQ(R) product line in important countries such as Spain, Portugal, Turkey, Egypt, Mexico, Brazil and Argentina. aap plans to publish the full Q3 2012 report on November 12, 2012. This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. ______________________________________________________ aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets - aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de. For inquiries please contact: aap Implantate AG, Marc Heydrich, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, m.heydrich@aap.de 01.10.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated July 03, 2012, 11:13 AM

aap Implantate AG: aap preliminary report: strong H1 2012 growth (Sales: +33%); Further increase of sales forecast for the financial year 2012 to EUR 35.5 million

				
					

aap Implantate AG: aap preliminary report: strong H1 2012 growth (Sales: +33%); Further increase of sales forecast for the financial year 2012 to EUR 35.5 million

aap Implantate AG / Key word(s): Half Year Results/Forecast 03.07.2012 11:13 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad-hoc Announcement in accordance with § 15 of the German Securities Trading Act (WpHG) aap preliminary report: strong H1 2012 growth (Sales: +33%); Further increase of sales forecast for the financial year 2012 to EUR 35.5 million Berlin, July 3, 2012 Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE), a global medical device company focused on innovative trauma products and biomaterials for the orthopaedic market, achieved 33% sales growth in the first half of the financial year 2012 with sales of EUR 18.8 million (previous year: EUR 14.1 million). Compared with the previous year, sales in the second quarter of 2012 rose by 17% to EUR 8.9 million from EUR 7.6 million. The first-half year-over-year growth was driven by higher product sales (EUR +2.5 million) and a new exclusive license agreement (EUR +2.2 million) signed in March 2012. Based on the sales results for the first three months of 2012, the Company anticipates first half 2012 EBITDA growth to be more than 50% and first half 2012 EBIT growth to exceed 100% as compared to the first half of 2011. The EBITDA in the second quarter of 2012 will not develop in the same way as the sales because of non-recurring one time effects in the second quarter of 2011 amounting to EUR 0.4 million. 2012 (in EUR million) 2011 (in EUR million) Change Sales Q1 9.9 6.5 +51% Q2e* 8.9 7.6 +17% H1e* 18.8 14.1 +33% EBITDA Q1 2.1 0.8 >100% Q2e* 1.1 - 1.4 1.3 -15% to +8% H1e* 3.2 - 3.4 2.1 +52% to +62% *expected figures for the respective period Based on the strong results for the first an second quarter of 2012, the Company is increasing its sales forecast to approximately EUR 35.5 million for the financial year 2012, a corresponding growth of 22%. For the EBITDA the management board expects an increase of more than 25% to approximately EUR 5.2 million for the financial year 2012. On the basis of, among other things, the current order intake, the Management Board anticipates for the third-quarter 2012 sales of EUR 7.6 million to EUR 8.0 million, corresponding to sales growth of 10% to 16%. For the first nine months of 2012, the Company expects sales growth of 26% to 28%. For the first nine months of 2012, the Management Board expects year-on-year EBITDA and EBIT growth of more than 40% and 100%, respectively, as compared to the first nine months of 2011. 2012e (in EUR million) 2011 (in EUR million) Change Sales Q3 7.6 - 8.0 6.9 +10% to +16% 9m 26.4 - 26.8 21 +26% to +28% EBITDA Q3 0.9 - 1.2 0.8 +13% to +50% 9m 4.1 - 4.7 2.9 +41% to +62% aap plans to publish its full Q2 2012 report on August 14, 2012. This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. 03.07.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated April 03, 2012, 10:25 AM

aap Implantate AG: 51% sales increase to EUR 9.8 million in the first quarter 2012

				
					

aap Implantate AG: 51% sales increase to EUR 9.8 million in the first quarter 2012

aap Implantate AG / Key word(s): Development of Sales/Quarter Results 03.04.2012 10:25 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Preliminary figures indicate that aap Implantate AG (XETRA: AAQ.DE), a global medical device company focused on innovative trauma products and biomaterials for the orthopaedic market, achieved total sales in the first quarter of 2012 of EUR 9.8 million, a 51% increase on the previous year's figure of EUR 6.5 million. The sales growth was driven by an 18% increase in sales on product level to EUR 7.7 million (previous year: EUR 6.5 million) as well as from the sales of EUR 2.1 million from the exclusive license agreement with a world-leading medical technology company announced on March 23, 2012. Based on the sales on product level in the first quarter 2012 and the Company's goal of achieving profitable growth, the Company anticipates that EBITDA growth on product level in the first quarter 2012 will be stronger than the sales increase on product level. In addition, based on the sales on product level for the first quarter 2012, the management board of aap is reiterating its full year 2012 outlook for a 10% sales increase on product level. The Company's Q1 2012 report is scheduled for publication on May 15, 2012. Contact: aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; m.heydrich@aap.de 03.04.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated March 23, 2012, 12:07 PM

aap signs exclusive license agreement for an IP-protected product of its biomaterial portfolio

				
					

aap signs exclusive license agreement for an IP-protected product of its biomaterial portfolio

aap Implantate AG / Key word(s): Contract/Agreement 23.03.2012 12:07 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap Biomaterials GmbH, a subsidiary of aap Implantate AG, a medical technology company listed in the Frankfurt Stock Exchange's Prime Standard segment, today signed an exclusive license agreement with a world-leading medical technology company. aap has granted an exclusive license to an IP-protected product of its biomaterial portfolio and remains at the same time the product's manufacturer. The exclusive license relates to all product indications, excluding Dental, oral care and food additives and is valid worldwide except in the United States. With the signing, aap will receive a one-time license fee of approx. EUR 2.1 million. Contact: aap Implantate AG; Marc Heydrich; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 134; Fax.: ++49/30/750 19 - 290; m.heydrich@aap.de 23.03.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated April 28, 2011, 04:28 PM

aap Implantate AG: Capital Increase of approx. 10%

				
					

aap Implantate AG: Capital Increase of approx. 10%

aap Implantate AG / Key word(s): Capital Increase 28.04.2011 16:28 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- The Management Board of aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, decided today with the Supervisory Board's approval to increase its capital stock from authorized capital by EUR 2,788,186. This corresponds to approx. 10% of the present capital stock. The 2,788,186 new shares are subscribed, excluding rights entitlement for existing shareholders, by way of a private placement in return for a cash contribution at a price of EUR 1.09 per no-par share. The company's capital stock thereby increases by EUR 2,788,186 from the present EUR 27,881,870 to EUR 30,670,056. The inflow of funds of approx. EUR 3 million from the capital increase is to serve the purpose of funding further growth by launching new products and entering new markets in Europe and the United States of America as well as strengthening the financial basis of aap. 28.04.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: info@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated March 26, 2010, 07:46 PM

aap Implantate AG: Appointment of a new member of the Management Board / Early extension of CEO's contract

				
					

aap Implantate AG: Appointment of a new member of the Management Board / Early extension of CEO's contract

aap Implantate AG / Change of Personnel 26.03.2010 19:46 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- aap Implantate AG, a medical technology company listed in the Prime Standard segment of the Frankfurt Stock Exchange, has strengthened its top management level. Today, the Supervisory Board has appointed Marek Hahn with effect from April 1st as a new member of the Management Board for the period April 1st until December 31st, 2012. Alongside Mr. Biense Visser (CEO) and Mr. Bruke Seyoum Alemu (COO), Mr. Hahn, as Chief Finance Officer (CFO), will be in charge of the divisions Finance, IT, Human Resources and Administration. Also, the contract of Mr. Visser has been extended early for another two years until the 31st of December 2012. Since April 2007, Mr. Hahn (35) has been serving as Director of Finance for aap. Prior to that, he worked for many years for KPMG Deutsche Treuhandgesellschaft AG in the field of Auditing, Accounting and Executive Consulting in various positions in Germany and foreign countries. Mr. Hahn possesses comprehensive knowledge in the area of Finance and Controlling. Rubino di Girolamo - Chairman of the Supervisory Board: 'We are glad to have accomplished the early extension of Mr. Visser's contract. Being a very successful manager and a company leader for many years, Mr. Visser will manage, together with the extended Management team, the company's fortune in the future. With Mr. Hahn, aap was able to bind a Finance expert. With these decisions, aap was able to accomplish important pre-conditions to achieve the goal of a sustainable profitable growth as well as to develop aap to become an innovative product leader.' Kontakt: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications & Legal Affairs; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 133; Fax.: ++49/30/750 19 - 290; n.huedepohl@aap.de 26.03.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hannover, München, Hamburg, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated August 31, 2009, 02:23 PM

aap signs license agreement with a EUR 3.0 million total value

				
					

aap signs license agreement with a EUR 3.0 million total value

aap Implantate AG / Agreement 31.08.2009 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- EMCM B.V., a Dutch subsidiary and member of the aap Implantate AG Group, a medical technology company listed in the Frankfurt Stock Exchange's Prime Standard segment, today signed with a distribution partner an open-ended exclusive license agreement on the utilization of the intellectual property of a product in the field of medical aesthetics with a total value of EUR 3.0 million. By the terms of the agreement, aap will continue to manufacture and supply the product under contract. This contract relate to a line of business that is no longer core business area for aap and clearly testify to the implementation of the Group's strategic realignment and its focus on Ortho/Trauma/Spine business. Due to the effects of the above-mentioned contract at the sales and earnings level, the aap Management Board sees its forecast of profitable growth this financial year confirmed. It specifically anticipates an EBITDA of between EUR 5.0 million and EUR 7.0 million. Together with another recent contract with a global partner to supply bone cement for use in spinal surgery and traumatology, also the groundwork for business development in 2010 is laid. Shipping of the bone cement will begin in the current financial year, and the signing of this agreement confirms once again aap's leading position in this field. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications & Legal Affairs; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 133; Fax.: ++49/30/750 19 - 290; n.huedepohl@aap.de 31.08.2009 Financial News transmitted by DGAP --------------------------------------------------------------------------- Language: English Company: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hannover, München, Hamburg, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated April 16, 2009, 09:12 PM

aap expects in the annual consolidated financial statements 2008 one time, non-cash effect adjustments amounting to approx. EUR 6.5 million

				
					

aap expects in the annual consolidated financial statements 2008 one time, non-cash effect adjustments amounting to approx. EUR 6.5 million

aap Implantate AG / Strategic Company Decision/Restructure of Company Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Within the compilation of the annual consolidated financial statements to the 31st of December 2008, write-offs totaling approx. EUR 6.5 million have been stated. These one time and non-liquidity-related adjustments in the annual consolidated financial statements according to IFRS result mainly from the new strategic direction and the announced restructuring measures of the aap group. The focusing of aap on the Ortho/Trauma/Spine areas led to an extraordinary write-off of capitalized services totaling approx. EUR 4.0 million. The new strategic direction led among other things to a new prioritization of research and development projects in the core business segments Ortho, Trauma & Spine as well as the classification of some business lines (among others medical aesthetics) as non-core business segments. Development projects of those non-core business segments were terminated and extraordinary depreciated. In addition to that, legal uncertainties regarding ongoing negotiations led to an extraordinary write off of intangible assets totaling approx. EUR 1.4 million. Other adjustments to the amount of EUR 1.1 million result from the execution of cost reduction and restructuring measures like the relocation of the aap bio implants markets GmbH to Berlin and the subsequent closure of the site in Düsseldorf as well as the annual impairment tests of inventories within the compilation of the annual consolidated financial statements. Due to the above mentioned adjustments impacts on the amount of the deferred taxes occur. The change of the deferred tax liabilities result mainly of the adjustments within the purchase price allocation of capitalized intangible assets as well as original capitalized services. In the financial year 2008 aap capitalizes, in accordance with the IFRS, deferred tax assets based on the anticipated use of the carryforward of unused tax losses only to the extent that aap has sufficient deferred tax liabilities. A deferred tax income amounting to approx. EUR 0.2 million occurs out of the juxtaposition of the tax effects resulting from the above mentioned measures. All of the above mentioned figures are based on the unaudited annual consolidated financial statements 2008 of the aap Implantate AG and therefore might still change. aap Implantate AG's audited annual consolidated financial statements for 2008 will be published on April 28, 2009. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications & Legal Affairs; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 133; Fax.: ++49/30/750 19 - 290; n.huedepohl@aap.de 16.04.2009 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated March 16, 2009, 04:44 PM

aap Implantate AG: Capital Increase as part of the performance-improvement program

				
					

aap Implantate AG: Capital Increase as part of the performance-improvement program

aap Implantate AG / Corporate Action Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- The Management Board of aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, decided today with the Supervisory Board's approval to increase its capital stock from authorized capital by approx. 5%, or EUR1,267,357. The new shares are subscribed today, excluding rights entitlement for existing shareholders, by way of a private placement in return for a cash contribution at a price of EUR 1.00. The company's capital stock thereby increases by EUR 1,267,357 from the present EUR 26,614,513 to EUR 27,881,870. Within a financing commitment of a shareholder of EUR 2 million and the funds of the above mentioned capital increase, aap obtains a total inflow of approx. EUR 3.3 million. Alongside, aap was able to accomplish a release of a shareholder's loan of EUR 0.5 million. These measures serve the purpose of securing the corporate finance and are a component of aap's performance-improvement program, which include the optimization of the capital structure, cost reduction measures, simplifying the organizational structure, divestiture of non-core business units, pushing a profitable company growth as well as maintaining the existing innovation pace. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications & Legal Affairs; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 - 133; Fax.: ++49/30/750 19 - 290; n.huedepohl@aap.de 16.03.2009 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated December 16, 2008, 02:22 PM

aap Implantate AG: aap reduces growth expectation for fiscal 2008

				
					

aap Implantate AG: aap reduces growth expectation for fiscal 2008

aap Implantate AG / Change in Forecast Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, will achieve a growth in sales, but not of the 20% planned. The reduction of the sales targets is due to the Biomaterials division falling well behind its projected sales in the fourth quarter. The main reasons for this are the significant changes in environmental customers’ order behavior (reduction of inventories) as well as delays in planned approvals of new products. Fourth-quarter growth expectations of the Biomaterials division will be below expectations, so aap does not anticipate a year-on-year improvement on the very strong fourth quarter of 2007 (Q4/2007: sales EUR 6.3 million). The Trauma & Orthopaedics division has shown in the fiscal 2008 a significant overall above-average improvement in sales as well as the result and therefore could continue last year’s growth trend with a significant double digit sales increase. The reduced growth expectation for the entire company will have negative implications on the planned overall company result. That is why aap is preparing an extensive cost reduction program to offset the reduced growth expectations in 2008 and achieve a marked result improvement in 2009. In view of sales developments to date and of one-time effects due to cost reductions and possible value adjustments, the full-year overall result will probably not reach its previous years earnings before taxes on income of EUR 2.4 million. The company plans to publish interim full year 2008 sales figures during January 2009. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications & Legal Affairs; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 133; Fax.: ++49/30/750 19 – 290; n.huedepohl@aap.de 16.12.2008 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated November 28, 2008, 08:01 AM

aap Implantate AG: Management Board Changes at aap Implantate AG: Biense Visser New CEO

				
					

aap Implantate AG: Management Board Changes at aap Implantate AG: Biense Visser New CEO

aap Implantate AG / Change of Personnel Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, has named Biense Visser, 56, currently a member of aap’s Supervisory Board and CEO of the Dutch company De Ruiter Seeds B.V., as the new chief executive officer of aap Implantate AG. Today, the Supervisory Board appointed him as a member of the Management Board and, with effect from January 1, 2009, as the Board’s chairman. In addition to his work as CEO, Mr. Visser will also be in charge of Finance. Biense Visser is a Dutch citizen, studied pharmacy, holds an MBA and has many years’ experience as a CEO of various pharmaceutical and healthcare companies. In taking up his appointment at aap, Mr. Visser will stand down as Board Chairman of De Ruiter Seeds B.V., Bergschenhoek, The Netherlands. His place on aap’s Supervisory Board will be taken by Ronald Meersschaert, 46, who was elected as a substitute member of the Supervisory Board at the last Annual General Meeting. Mr. Meersschaert is currently a partner in the private equity company Boekhoorn M. & A. B.V., Arnhem, The Netherlands. With effect from December 1, 2008, the Supervisory Board named Bruke Seyoum Alemu as Chief Operating Officer. In this function he will be as a member of the Management Board in charge of Development, Production, Sales and Marketing at the aap Group. Oliver Bielenstein is leaving by mutual agreement as of December 31, 2008, as the company’s CFO and Board member in charge of the medical biomaterials division. Mr. Bielenstein will continue to be at aap’s service as a consultant. The Management Board and Supervisory Board of aap Implantate AG would like to thank Mr. Bielenstein for his commitment over the past four years and for successfully developing the Group’s biomaterials division. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications & Legal Affairs; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 133; Fax.: ++49/30/750 19 – 290; n.huedepohl@aap.de 28.11.2008 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated September 03, 2008, 09:50 AM

aap closed 5% Capital Increase successfully

				
					

aap closed 5% Capital Increase successfully

aap Implantate AG / Capital Increase Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, has successfully completed its yesterday announced 5% capital increase. The capital increase was placed in full by an issue of 1,267,357 shares at a price of EUR 2.18 apiece. Until the registration of the implementation of the capital increase and the listing of the new shares – expected to be effected end of September 2008 – a major shareholder of the company made own shares available by a temporary securities loan for the investors supply. Subject to the recording of the capital increase in the commercial register the company’s capital will increase by EUR 1,267,357 from the present EUR 25,347,156 to EUR 26,614,513, divided into the same number of registered shares. From the capital increase the company receives more than EUR 2.7, intended to serve the purpose of funding further growth. Contact: Please address any queries to: aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications & Legal Affairs; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 133; Fax.: ++49/30/750 19 – 290; n.huedepohl@aap.de 03.09.2008 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated September 02, 2008, 12:08 PM

aap Implantate AG plans 5% Capital Increase

				
					

aap Implantate AG plans 5% Capital Increase

aap Implantate AG / Capital Increase Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- The Management Board of aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange in the Prime Standard segment, decided today with the Supervisory Board’s approval to increase its capital stock from authorized capital by up to 5%, or up to €1,267,357. The new shares are to be offered to interested investors, excluding a rights entitlement for existing shareholders, by way of an accelerated private placement in return for a cash contribution at a price close to the present market price. A public offering will not take place. The transaction is to be implemented at short notice subject to the market situation. The inflow of funds from the capital increase is to serve the purpose of funding further growth. A further aim is to widen the institutional shareholder base by means of the placement. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Investor & Public Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 133; Fax.: ++49/30/750 19 – 290; n.huedepohl@aap.de 02.09.2008 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated September 20, 2007, 06:44 PM

aap Implantate AG: Fame Medical Group Takeover Completed Successfully

				
					

aap Implantate AG: Fame Medical Group Takeover Completed Successfully

aap Implantate AG / Acquisition/Capital Increase Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- aap today completed the acquisition of all shares in the Dutch FAME Holding B.V. Group and its subsidiaries with the commercial register entry. The capital increase by a contribution in kind agreed at the extraordinary general meeting of aap Implantate AG held on February 15, 2007 was today entered into the commercial register. Lawsuits filed by individual shareholders had delayed the entry. aap thereupon embarked on fast track proceedings, an option available since 2006 that is intended to enhance the legal and procedural security of companies affected by lawsuits filed in connection with shareholders’ meetings. The register entry increases aap Implantate AG’s capital stock by EUR 8,448,999.00 to EUR 25,347,156.00, divided into 25,347,156 individual share certificates. Listing of the new shares for stock market trading is planned for the weeks ahead. Due to contractual provisions 50 percent of the new shares are subject to a 12-month lock-up period after listing. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Nanette Hüdepohl; Investor & Public Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 133; Fax.: ++49/30/750 19 – 290; n.huedepohl@aap.de 20.09.2007 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated June 20, 2007, 12:15 PM

aap Implantate AG: aap focus on implantable biomaterials

				
					

aap Implantate AG: aap focus on implantable biomaterials

aap Implantate AG / Strategic Company Decision Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- aap Implantate AG, a medical technology company listed in the Prime Standard Segment on the Frankfurt Stock Exchange and specialized in biomaterials and implants for trauma and joint reconstruction, will in the future focus solely on implantable medical biomaterials. After acquiring the Dutch biomaterials specialist Fame Medical Group, aap will in 2007 earn more than 70 percent of planned consolidated sales totaling around EUR 30 million in this segment. In the months ahead various strategic options will be investigated for the Trauma/Joint Reconstruction division, located in Berlin. Initially, subject to approval by the annual meeting of shareholders planned for August 27, 2007, this unit with around 90 employees is to be transferred to a separate subsidiary. For 2007 aap plans double-digit sales growth in this segment. For aap, focusing on implantable biomaterials in the core areas bone cements, bone replacement materials, infection therapy and tissue generation means concentrating on fast-growing and profitable niche markets. In these markets aap is already a worldwide technology leader and has in recent years built up development and sales partnerships with world-leading orthopedic, spinal column and dental enterprises. To visualize the realignment aap plans to rename the parent company aap BioImplants AG. DGAP 20.06.2007 ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de www: www.aap.de ISIN: DE0005066609 WKN: 506660 Indices: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated September 24, 2006, 11:28 AM

aap Implantate AG:Talks for Dutch FAME Medical Group

				
					

aap Implantate AG:Talks for Dutch FAME Medical Group

aap Implantate AG / Acquisition Ad hoc announcement according to § 15 WpHG transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Ad-hoc Announcement in accordance with § 15 of the German Securities Trading Act (WpHG) Berlin, September 24, 2005 aap Holds Takeover Talks for Dutch FAME Medical Group aap Implantate AG, a medical technology company listed in the Frankfurt Stock Exchange’s Prime Standard segment and specialized in biomaterials and implants for traumatology and orthopedics, has agreed in a letter of intent on the main features of a merger with Dutch biomaterials group FAME Medical, including its subsidiaries EMCM (European Medical Contract Manufacturing), Bactimm, TPI (Tissue Processing International) and FMP (Fame Medical Products). The transaction, which is subject to the findings of reciprocal due diligence, to approval by the general meeting of aap Implantate AG shareholders, and to exemption from a takeover bid, will probably take the form of a contribution of shares in the FAME Group to aap and thereby be a pure share transaction. The present temporary exchange ratio being 1 to 2, FAME Group shareholders would on completion of the transaction hold around 33% of aap stock. The intention is to complete the transaction after approval by an extraordinary meeting of aap shareholders that has yet to be convened but will probably be held in Q1 2007 with the merger being retroactive from January 1, 2007. aap’s biomaterials division, which already accounts for 70% of aap Group sales revenues, and the FAME companies to a very large extent do business in the same segments (bone cements, bone graft substitutes, tissue processing & regeneration), but do so with a complementary product range. The two companies have collaborated for several years. The alliance of the two will create a leading European biomaterials company that is focused, with a comprehensive product range, on development, production and clinical marketing in cooperation with international sales partners. Both companies have a well-filled pipeline with promising and complimentary products to be approved and introduced to the market within the upcoming quarters. The FAME Group’s 2005 sales revenues were € 7.6 million (aap 2005: € 13.3 million) and its EBIT and results structure to IFRS is comparable with aap’s. For the coming years FAME expects an solid double-digit organic growth. Both companies stand to realize from the transaction considerable synergy potentials in R&D, production and sales. For 2007 aap expects to be able to report the first positive profits contributions from this transaction. Contact: Bei Rückfragen wenden Sie sich bitte an: aap Implantate AG; Oliver Bielenstein; CFO; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 140; Fax.: ++49/30/750 19 – 290; o.bielenstein@aap.de DGAP 24.09.2006 ---------------------------------------------------------------------- Language: English Issuer: aap Implantate AG Lorenzweg 5 12099 Berlin Deutschland Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: aap@aap.de WWW: www.aap.de ISIN: DE0005066609 WKN: 506660 Indices: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Hannover, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Insider Information according to Article 17 MAR dated September 27, 2005, 05:47 PM

completes capital increase

				
					

completes capital increase

aap Implantate AG, a German medical technology company specialized in healing bone fractures, joint replacement, bone cements and biomaterials segments, has successfully completed a capital increase with subscription rights. The capital increase was placed in full by an issue of 1,460,857 registered shares. The shares that were not taken up as rights were strongly oversubscribed.

Subject to the recording of the capital increase in the companies’ register of Charlottenburg district court, Berlin, the company’s capital stock will increase by EUR 1,460,857 from the present EUR 15,058,300 to EUR 16,519,157, divided into the same number of registered shares. The new shares are likely to be included in the existing Frankfurt stock exchange listing from the beginning of October 2005. From the capital increase the company receives EUR 2.3 million before transaction costs. The proceeds are intended to be used for financing an acquisition in the biomaterials segment and to continue to step up its operative business.
Insider Information according to Article 17 MAR dated August 31, 2004, 08:32 AM

Publication of first-half 2004 figures

				
					

Publication of first-half 2004 figures

aap Implantate AG, a medical technology company specialized in bone growth and replacement substances, fracture healing and joint replacement, took a 5.2% year-on-year decline in Group sales to EUR 5.8 million in the first half of 2004 due to liquidity-related delivery difficulties. At the same time, it made further negative value adjustments totaling around EUR 3.5 million on various balance sheet items that had an enormous influence on the result.

In the first six months of 2004 the company's EBITDA was EUR 645,000 (previous year: EUR 493,000). EBIT at minus EUR 203,000 was an improvement on the previous year's minus EUR 1 million. The DVFA/SG consolidated result for the reporting period on which the above-mentioned figures are based was minus EUR 1.2 million (previous year: minus EUR 1.1 million) and DVFA/SG earnings per share were minus EUR 0.25 (previous year: minus EUR 0.22).

The EUR 9.7 million capital increase successfully completed in August that will only be shown in the figures for the third quarter, along with the entry of a new group of investors and massive balance sheet value adjustments, have put the company back on a sound financial base. aap must now make use of its newly gained financial security and independence and convert them into operating successes.

Insider Information according to Article 17 MAR dated August 10, 2004, 07:30 PM

Capital increase concluded successfully

				
					

Capital increase concluded successfully

aap Implantate AG, a medical technology group specialized in fracture healing, joint replacement and biomaterials, has brought to a successful conclusion a capital increase and rights issue. The capital increase was placed in full by the issue of 9,739,058 ordinary shares, of which around 1.4 million were acquir-ed by existing shareholders and the remainder by new investors, employees and individuals associated with the company. After the successful placement and entry of the capital increase in the commercial register at Berlin's Charlotten-burg district court, the company's capital stock will increase by EUR 9,739,058 from the present EUR 4,869,529 to EUR 14,608,587, consisting of 14,608,587 ordinary shares. The new shares will probably be listed along with the existing shares on the Frankfurt stock exchange in mid-September 2004.

The capital increase will result in a gross inflow of funds amounting to around EUR 9.7 million that is intended to be used to redeem in full all outstanding loans and to repay trade creditors and other liabilities. The remaining funds are to be used to boost sales and to develop and launch new products.
Insider Information according to Article 17 MAR dated May 28, 2004, 05:20 PM

aap Implantate AG: Financing concept agreed

				
					

aap Implantate AG: Financing concept agreed

aap, banks and investors reach agreement/Liquidity made available/New Board member strengthens management/Extraordinary value adjustments are the hallmark of annual financial statements for 2003

aap concluded agreements today with a group of German and Swiss financial investors and its existing committed banks on a reconstruction and recapitalization of the company.

Subject to approval of the capital measures by the annual shareholders' meeting, to successful implementation of the capital increase and to approval of it by the German regulatory authority BAFin, the agreements reached between the company, banks and investors will overcome aap's financial crisis and provide the company with fresh liquidity.

The concept is based for one on a guarantee by the investors to fund a capital increase in cash for the company of at least EUR 8 million and a maximum of EUR 10 million at a share price of EUR 1.00. Shareholders' stock options rights will be upheld in connection with the capital increase. Further details will be announced shortly. In addition, the investors will shortly provide an EUR 800,000 bridging loan to keep the company solvent until the capital increase. In return, aap undertakes to pay off its existing bank loans of nearly EUR 11 million from the banks at a reduced rate of approx. EUR 5 million once the capital increase in cash has been successfully implemented.

Along with the financial consolidation the company will be making personnel changes. Oliver Bielenstein, previously a partner in Ernst & Young AG, Switzerland, has joined the Board as the new CFO. Uwe Ahrens, the company's founder and CEO, will retain his role. Bruke Seyoum Alemu, the previous CFO, will in future be in charge of sales and marketing on the Management Board. Changes in membership of the Supervisory Board are envisaged and are likely to be announced with the invitation to attend the annual shareholders' meeting.

As a part of the negotiations with investors, the Management Board has drawn up a consolidation concept that provides for a number of strategic adjustments as a precondition for the recapitalization commitment. These strategic adjustments led to additional value adjustment requirements in the company's balance sheet, but none with an effect on liquidity. These value adjustments apply mainly to intangible assets, with the result that the provisional consolidated net loss for fiscal 2003 as announced in April will increase to EUR 15.4 million. Consolidated equity capital as at Dec. 31, 2003 totaled EUR 6.3 million and the equity ratio was around 23%. Once the capital increase has been implemented, the company's equity before consolidation profits will increase to more than EUR 14 million.

The consolidated annual financial statement 2003 along with the management report is available on the company's website as of today. The report for the first quarter of 2004 will be published on June 11, 2004, and the annual shareholders' meeting will probably be held in July 2004.

Insider Information according to Article 17 MAR dated April 07, 2004, 03:39 PM

Provisional figures for financial year 2003

				
					

Provisional figures for financial year 2003

Earnings burdened by special effects and risk provision

aap Implantate AG, a specialist in the field of artificial and biomedical implants for the muscular-skeletal organ system, after preliminary analysis reports consolidated sales of roughly EUR 11 million in the financial year 2003. However, this was 18% down on the previous year.

Before acquisition-related depreciation and stock options, the company's 2003 EBITDA was minus EUR 0.273 million (previous year: EUR 1.607 million). Adjusted for these factors, the operating result was minus EUR 3.183 million and was
therefore down on the previous year's EUR 0.097 million. Without taking into account acquisition-related depreciation and stock options, DVFA/SG consolidated result in the review period totaled minus EUR 3.170 million (previous year: minus EUR 3.066 million) and DVFA/SG earnings per share were minus EUR 0.66 (previous year: minus EUR 0.64).

After taking into account acquisition-related depreciation and stock options, the figures were as follows: EBITDA minus EUR 0.273 million (previous year: EUR 1.027 million) and operating result minus EUR 4.645 million (previous year: minus EUR 1.944 million). DVFA/SG consolidated result amounted to minus EUR 4.180 million (previous year: minus EUR 4.429 million) and DVFA/SG earnings per share were minus EUR 0.87 (previous year: minus EUR 0.93).

In addition to acquisition-related depreciation, the results for financial year 2003 are burdened by other special effects and extensive risk provision totaling EUR 3 million. This is essentially attributable to the following factors: write down of receivables, reserves for the risks and costs of litigation, downward valuation adjustments of inventories, granting a rebate to the contributors of the Mebio/Coripharm group of companies, extraordinary depreciation of land and buildings, provisions for impending losses due mainly to currency risks in our foreign business, and consulting expenses for capital procurement.

Thanks to resolute implementation of the restructuring measures initiated, which also involve restructuring and strengthening the sales and marketing segment, there was already a positive trend in the first quarter of 2004. The goal is to achieve the turnaround in 2004. An important prerequisite for doing so is to secure the company's funding. To ensure this, we are currently engaged in discussions with our own banks and with potential financial investors. We expect to conclude these negotiations during the second quarter.
Insider Information according to Article 17 MAR dated November 28, 2003, 08:45 AM

Nine-month 2003 figures published

				
					

Nine-month 2003 figures published

In  the  first nine months of the financial year 2003, the subdued business trend  continued  at  aap  Implantate  AG,  a  specialist in artificial and biomedical  implants  for  the muscular-skeletal organ system. Consolidated sales revenues to September 30, 2003 were, at EUR 8.7 million, around 15.5% down  on the year. Restraint continued to characterize ordering behavior in Germany,  and  the  revival  of business in Asia on the basis of a purchase agreement  already  signed  will only lead to positive sales stimuli at aap from the current quarter onward.

Before special factors (acquisition-related depreciation and stock options) the company's EBITDA in the first nine months totaled EUR 852,000 (previous year:  EUR  2.027 million). The adjusted operating result amounted to minus EUR  589,000  and  was  therefore  down  on  the  previous year's EUR 1.182 million.  The  DVFA/SG  consolidated  result  before special factors in the reporting  period  was  minus  EUR  1.148 million (previous year: minus EUR 163,000) and DVFA/SG earnings per share were minus EUR 0.24 (previous year: minus EUR 0.03).

Taking  the  above-mentioned special factors into account, the figures were as  follows:  EBITDA was EUR 852,000 (previous year: EUR 1.585 million) and the  operating result was minus EUR 1.685 million (previous year: minus EUR 299,000).  The  DVFA/SG  consolidated  result  was  minus EUR 1.906 million (previous  year:  minus  EUR  1.134 million) and DVFA/SG earnings per share were minus EUR 0.40 (previous year: minus EUR 0.24).

Four  new  products are seen as aap's growth drivers in the quarters ahead. The  European  approval  of  the  company's  newly  developed synthetic bone substitute  PerOssal®  will  further extend its competence in orthobiology. aap  plans  to expand its endoprosthetics product portfolio before the year is  out  by  launching its new products AEQUOS® and VarioFit®. The positive response  to aap's innovative stable-angle plates for treating fractures of the  upper  and  lower  arm given by specialists at both this year's German Orthopedists'  Congres and at the Medica trade fair is seen as confirmation of the market prospects of this new development in osteosynthesis too.

Insider Information according to Article 17 MAR dated September 10, 2003, 12:00 AM

aap Implantate AG: aap receives approval for bone replacement material

				
					

aap Implantate AG: aap receives approval for bone replacement material

aap  Implantate  AG, a specialist in artificial and biomedical implants for the  musculoskeletal  organ  system, has received European approval for the innovative  bone  replacement material PerOssal®. PerOssal® is designed for use   as   a   permanent  filler  or  for  bone  defect  reconstruction  in traumatology, orthopedic, dental, oral and maxillofacial surgery.

PerOssal®,  a  newly  developed synthetic bone replacement material, offers two   important  advantages  over  comparable  products  that  are  already established in the market. PerOssal® is the first bone replacement material that can be implanted into infected bone defects after surgical cleaning of the  wound  at  the same time as antibiotics are administered. In this way, for  example,  it  will  be  possible  in  the future to select antibiotics targeted  in  accordance  with  the  patient's microbiological findings and administer  them  individually.  Until  now,  it  has  not been possible to implant  bone replacement materials in previously infected areas on account of  the  risk  of  residual  germ  infection.  PerOssal®'s second important property is its swift and total resorbability that enables the defect to be filled  fast with new bone material of the body's own, with the result that the  patient  can  be  spared  further  surgery  to remove the implant. The PerOssal®   ingredient   that   performs   this   task,  a  nanocrystalline hydroxylapatite, is already marketed by aap in Germany as Ostim®.

For  bone  replacement  materials  Merrill  Lynch  forecasts a world market volume  of up to $ 700 million this year and annual growth rates of between 40%  and  45%.  PerOssal®  opens up a new therapy concept for physicians by linking bone replacement and local wound healing. The product's ease of use and  the  ability  to  combine  it  freely  with  different  agents make it attractive  for  users  from  economical  viewpoints  too.  Along  with its existing  products  Cerabone®  and  Ostim®,  aap  Implantate  AG is thereby extending further its competence in orthobiology.
Insider Information according to Article 17 MAR dated August 29, 2003, 12:00 AM

aap Implantate AG: Publication of first-half 2003 figures

				
					

aap Implantate AG: Publication of first-half 2003 figures

In the second quarter of 2003, the moderate business trend at aap Implantate AG, a specialist in artificial and biological implants for the muscular-skeletal organ system, continued. It was due in part to the strength of the euro and the consequences of the SARS epidemic. Consolidated sales revenues at EUR 6.1 million in the first half of 2003 were around 15% down on the previous year.

Before special factors (acquisition-related depreciation and stock options), the  company grossed EUR 493,000 in earnings before interest, taxes, depreciation and amortization in the first half of 2003 (previous year: EUR 1.954 million). The operating result adjusted in this way totaled minus EUR 233,000, or less than the previous year's EUR 1.462 million. DVFA/SG consolidated result before special factors was minus EUR 562,000 in the reporting period (previous year: EUR 306,000) and DVFA/SG earnings per share were minus EUR 0.12 (previous year: minus EUR 0.06).

Taking the above-mentioned special factors into account, the figures were as follows: EBITDA was EUR 493,000 (previous year: EUR 1.614 million), and operating result minus EUR 964,000 (previous year: EUR 392,000). The DVFA/SG consolidated result was minus EUR 1.067 million (previous year: minus EUR 406,000), DVFA/SG earnings per share were minus EUR 0.22 (previous year: minus EUR 0.09).

We will probably not be able to achieve our objective of double-digit profitable  sales growth for the current financial year. It will be difficult to offset the losses of the first half financial year fully by means of a more positive business trend in the third and fourth quarter. aap nonetheless anticipates in the second half of 2003 a recovery of business in Asia and further sales stimuliarising from reconstruction of our sales network in the United States. The new
AEQUOS knee endoprosthesis, the Variofit hip prosthesis system and the two bone replacement substances Cerabone and Ostim are scheduled to be launched successfully in the market before the year is over.

end of ad-hoc-announcement
Insider Information according to Article 17 MAR dated May 30, 2003, 09:50 AM

Corrected announcement

				
					

Corrected announcement

Corrected announcement on behlaf of the issuer:START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn todays Ad-hoc-announcement, in the first paragraph, instead of:' .. EUR 80,000 ... EUR 449,000 ... EUR 0.09 .. EUR 144,000..' it must read: '.. minus EUR 80,000 ... minus EUR 449,000 ... minus EUR 0.09 ... minus EUR 144,000..'.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn the second paragraph, instead of: ' ... EBIT EUR 445,000 ... EUR 701,000 ... EUR 0.15 ... EUR 31,000 ...' it must read: ' EBIT minus EUR 445,000 ... minus EUR 701,000 ... minus EUR 0.15 ... minus EUR 31,000 ...'START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe complete corrected announcement is:START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap Implantate AG: Publication of figures for first quarter of 2003START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGDifficult export business keynotes first quarterSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGFor aap Implantate AG, a specialist in artificial and biomedical implants for the musculo-skeletal organ system, the first quarter was characterized by difficult export business. Consolidated sales at EUR 2.9 million were approx. 14% down on the year, due mainly to what was highly reserved ordering behavior in the export business in general, and especially in the Asian region, that can surely be attributed in part to the strong euro. Before special factors (acquisition-related depreciations and stock options), the company earned in the first quarter an EBITDA of EUR 299,000 (previous year: EUR 1.178 million). Adjusted accordingly, EBIT was minus EUR 80,000, or less than the previous year's EUR 895,000. The unadjusted DVFA/SG consolidated result for the review period was minus EUR 449,000 (previous year: EUR 380,000) and DVFA/SG earnings per share were minus EUR 0.09 (previous year: EUR 0,08). Adjusted cash earnings were minus EUR 144,000 (previous year: EUR 535,000). In spite of this unpleasant earnings trend, cash flow at the operating level increased over the review period to EUR 651,000 from EUR 216,000 at the end of 2002.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGTaking the above-mentioned special factors into account, the figures were as follows: EBITDA was EUR 299,000 (previous year: EUR 1.008 million) and EBIT minus EUR 445,000 (previous year: EUR 361,000). The DVFA/SG consolidated result was minus EUR 701,000 (previous year: EUR 34,000), DVFA/SG earnings per share were minus EUR 0.15 (previous year: EUR 0.01), and DVFA/SG cash earnings amounted to minus EUR 31,000 (previous year: EUR 553,000).START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn spite of this first-quarter business trend that failed to meet expectations, aap Implantate AG plans to achieve double-digit profitable sales growth this fiscal year without taking acquisition-related depreciations into account. aap mainly anticipates positive growth stimuli from launches of new products such asSTART_OF_TAGBREND_OF_TAGthe two bone crafts Cerabone and Ostim from the orthobiology segment and the innovative VersaBond bone cement as well as the new AEQUOS knee system from the endoprosthethics segment.

Insider Information according to Article 17 MAR dated May 30, 2003, 12:00 AM

aap Implantate AG: Publication of figures for first quarter of 2003

				
					

aap Implantate AG: Publication of figures for first quarter of 2003

START_OF_TAGbEND_OF_TAGDifficult export business keynotes first quarterSTART_OF_TAG/bEND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGFor aap Implantate AG, a specialist in artificial and biomedical implants for the musculo-skeletal organ system, the first quarter was characterized by difficult export business. Consolidated sales at EUR 2.9 million were approx. 14% down on the year, due mainly to what was highly reserved ordering behavior in the export business in general, and especially in the Asian region, that can surely be attributed in part to the strong euro. Before special factors (acquisition-related depreciations and stock options), the company earned in the first quarter an EBITDA of EUR 299,000 (previous year: EUR 1.178 million). Adjusted accordingly, EBIT was minus EUR 80,000, or less than the previous year's EUR 895,000. The unadjusted DVFA/SG consolidated result for the review period was minus EUR 449,000 (previous year: EUR 380,000) and DVFA/SG earnings per share were minus EUR 0.09 (previous year: EUR 0,08). Adjusted cash earnings were minus EUR 144,000 (previous year: EUR 535,000). In spite of this unpleasant earnings trend, cash flow at the operating level increased over the review period to EUR 651,000 from EUR 216,000 at the end of 2002.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGTaking the above-mentioned special factors into account, the figures were as follows: EBITDA was EUR 299,000 (previous year: EUR 1.008 million) and EBIT minus EUR 445,000 (previous year: EUR 361,000). The DVFA/SG consolidated result was minus EUR 701,000 (previous year: EUR 34,000), DVFA/SG earnings per share were minus EUR 0.15 (previous year: EUR 0.01), and DVFA/SG cash earnings amounted to minus EUR 31,000 (previous year: EUR 553,000). START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn spite of this first-quarter business trend that failed to meet expectations, aap Implantate AG plans to achieve double-digit profitable sales growth this fiscal year without taking acquisition-related depreciations into account. aap mainly anticipates positive growth stimuli from launches of new products such as the two bone crafts Cerabone and Ostim from the orthobiology segment and the innovative VersaBond bone cement as well as the new AEQUOS knee system from the endoprosthethics segment.

Insider Information according to Article 17 MAR dated March 31, 2003, 12:00 AM

aap Implantate AG: Publication of consolidated financial statement for 2002

				
					

aap Implantate AG: Publication of consolidated financial statement for 2002

START_OF_TAGbEND_OF_TAGApprox. 11% sales growth to € 13.3 million, Clear increase in EBITDA excluding stock options to € 1.6 million, 2003 target: double-digit profitable sales growthSTART_OF_TAG/bEND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGAt aap Implantate AG, a specialist in biomedical implants for the musculo-skeletal system, the sales and earnings trend in fiscal 2002 was positive. Sales revenues were up € 1.4 million to € 13.3 million (previous year: € 11.9 million), due mainly to expansion of business activity in the Asian market.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGTotal operating performance was up clearly on the year to € 14.770 million (previous year: € 12.156 million). START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGEBITDA including stock options was increased to € 1.03 million (previous year: -€ 1.97 million). After taking into account acquisition-related depreciations totaling € 1.461 million and € 579,000 in stock options carried as expenses, EBIT improved markedly by € 2.834 million to -€ 1.853 million (previous year: -€ 4.687 million). START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGEBITDA excluding stock options improved to € 1.6 million (previous year: -€ 1.171 million). EBIT before acquisition-related depreciations and stock options was € 188,000, or € 2.635 million above the previous year's -€ 2.447 million. START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe marked improvements in operating result were due to restructuring measures implemented across the group, to the integration of corporate acquisitions, and to the creation of a uniform sales network throughout the group. The cost-reduction program initiated at the end of 2001 also achieved ongoing successes. Personnel expenditure was reduced markedly, the materials usage quota was reduced, and other operating expenditure was reduced in relation to total operating performance.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn the current business year aap's primary concern is to market intensively in Germany and abroad all the product systems developed successfully over the past three years. The focus of our activities will be on expanding our business in bone cement, launching our new ÆQUOS® knee endoprosthesis in the market and generating significant sales of our orthobiological products Cerabone® and Ostim®. In this process, our main sales region Germany will be of prime importance, but to ensure optimal use of these products' future potential, acquiring additional sales partners in the European region will be an important strategic element. START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap's medium- and long-term growth strategy calls in general for significant investment. In respect of the financing required for its implementation, aap is currently engaged in talks with potential strategic partners on possible market and product cooperation and equity procurement measures. START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe target for the 2003 business year is to achieve double-digit profitable sales growth excluding acquisition-related depreciations.

Insider Information according to Article 17 MAR dated November 29, 2002, 08:35 AM

aap achieves double-digit sales growth and markedly higher earnings

				
					

aap achieves double-digit sales growth and markedly higher earnings

aap achieves double-digit sales growth and markedly higher earningsSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGSales growth approx. 13%/EBITDA excl. stock options approx. 279% higher/Cash earnings increase by a clear 208%/aap reaffirms 2002 targetsSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap Implantate AG succeeded in the third quarter in maintaining the positive trend initiated at the beginning of fiscal 2002. Sales revenues in the first three quarters were up 12.7% on the year to approx. EUR 10.3 million from approx. EUR 9.1 million. EBITDA excluding stock options improved by approx. 279% to EUR 2.027 million (previous year: EUR 535,000). Excluding acquisition-related depreciations totaling EUR 1.04 million (previous year: EUR 1.135 million) and EUR 441,000 (previous year: EUR 623,000) in stock options that count as expenditure but do not affect the company's cash position, EBIT amounted to approx. EUR 1.027 million and was approx. EUR 1.413 million up on the year (previous year: -EUR 385,000). Without these special effects, EBT increased by roughly 110% from -EUR 998,000 to EUR 100,000. Adjusted in this way, DVFA/SG consolidated earnings in the reporting period were -EUR 163,000 (previous year: -EUR 705,000), and DVFA/SG earnings per share were -EUR 0.03 (previous year: -EUR 0.15). Cash earnings adjusted on this basis totaled EUR 753,000 (previous year: EUR 245,000).START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGDespite a strong year-on-year earnings increase, third-quarter results were down on the first half of 2002. Including the above-mentioned special effects (stock options and acquisition-related depreciations), figures are as follows: EBITDA increased to EUR 1.585 million (previous year: -EUR 88,000) and EBIT increasedSTART_OF_TAGBREND_OF_TAGmarkedly by EUR 1.493 million to -EUR 454,000 (previous year: -EUR 1.947 million). EBT increased to -EUR 1.382 million (previous year: -EUR 2.755 million). DVFA/SG consolidated earnings improved in the reporting period to -EUR 1.134 million from the previous year's -EUR 1.878 million, DVFA/SG earnings per share were -EUR 0.24 (previous year: -EUR 0.39), and DVFA/SG cash earnings were up nearly 300% to EUR 822,000 (previous year: EUR 205,000).

Insider Information according to Article 17 MAR dated October 02, 2002, 12:00 AM

aap signs license agreement on international marketing of AEQUOS

				
					

aap signs license agreement on international marketing of AEQUOS

Artificial and biological implant specialist aap Implantate AG has concluded a license agreement with HJS Gelenk-System GmbH. By the terms of the agree-ment, aap is to handle manufacturing and marketing of the AEQUOS knee endo-prosthesis and the surgical instruments required for the implant. In addition to the German market, aap also holds exclusive international marketing rights for other EU and EEA countries and for China and Japan. For all other coun-tries with the exception of the Americas, aap holds a non-exclusive license.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe AEQUOS prosthesis, developed by aap as part of an HJS development con-tract, is the first of its kind with joint surfaces modeled on nature and incorporating the resulting natural rolling and sliding behavior. In the AEQUOS knee the patient has an implant that is self-stabilizing and at the same time has a wide motion travel.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe new AEQUOS knee endoprosthesis has three decisive advantages: The surface contour, to which worldwide patent rights in the important markets are held, leads in standardized wear and tear trials to less abrasion. Muscular triggering of the joints follows accustomed patterns and also incor-porates an automatic interlock to prevent overstretching. The surgical in-struments specially developed by aap facilitate a precise implantation.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGAEQUOS was first presented to specialists at the Congress of German Orthopedic Surgeons, held in Berlin from Sept. 25 to 28, 2002, thereby opening a new chapter in the history of knee endoprosthetics.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn 2001, the European market for knee implants totaled USD 443 million, of which Germany with USD 168 million accounted for the lion's share (Market Dynamics: Knee Arthroplasty, Datamonitor, May 2002).START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIn taking on the additional marketing of knee endoprostheses, aap has reached an important milestone for the further expansion of its endoprosthetics segment in the direction of becoming a 'one-stop shop.' aap now offers customers the opportunity to acquire from a single source all product competencies from bone cement via cementing techniques to the knee implant and the requisite surgical instruments. aap expects marketing of the AEQUOS prosthesis with its cutting-edge technology to lead to a decisive improvement in its European market position.

Insider Information according to Article 17 MAR dated August 30, 2002, 07:31 AM

Above-average sales, earnings and cash flow growth

				
					

Above-average sales, earnings and cash flow growth

START_OF_TAGBEND_OF_TAG14% sales growth / EBITDA excl. stock options up approx. 218% / Cash earnings up markedly by approx. 121% / Positive outlook for full year 2002START_OF_TAG/BEND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap Implantate AG has succeeded in maintaining the positive trend of the first quarter in the second quarter too. First-half sales revenues were up 14% on the year to approx. EUR 7.18 million from approx. EUR 6.29 million. EBITDA excluding stock options increased by about 218% to EUR 1.95 million (previous year: EUR 615,000). Disregarding acquisition-related depreciations totaling EUR 731,000 (previous year: EUR 807,000) and stock options carried as assets totaling EUR 340,000 (previous year: EUR 415,000), EBIT amounted to approx. EUR 1.3 million and was thereby roughly EUR 1.29 million higher than the previous year's EUR 9,000. The DVFA/SG-adjusted consolidated result for the review period was EUR 306,000 (previous year: -EUR 275,000) and DVFA/SG earnings per share were EUR 0.06 (previous year: -EUR 0.06). DVFA/SG-adjusted cash earnings totaled EUR 894,000 (previous year: EUR 352,000). Taking into account the above-mentionedSTART_OF_TAGBREND_OF_TAGspecial effects (stock options and acquisition-related depreciations), the figures are as follows: EBITDA increased to EUR 1.61 million (previous year: EUR 200,000), while EBIT was up markedly by EUR 1.441 million to EUR 228,000 (previous year: -EUR 1.213 million). The DVFA/SG consolidated result for the review period could be improved considerably from the previous year's -EUR 1.02 million to -EUR 406,000. DVFA/SG earnings per share were -EUR 0.09 (previous year: -EUR 0.21), while DVFA/SG cash earnings increased by approx. 121% in the review period to EUR 912,000 (previous year: EUR 413,000). START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBEND_OF_TAGIssuer's information/explanatory remarks concerning this ad-hoc-announcement:START_OF_TAG/BEND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe integration of the acquired companies has been widely completed on all levels. In view of the successful course of business in the first half, aap Implantate AG has reconfirmed its targets for the full fiscal year 2002. The company reaffirms its forecast of profitable double-digit sales growth, excluding special effects (stock options and acquisition-related depreciations) for the full year 2002. The Management Board notes that aap has positioned itself outstandingly in the orthopedics growth market on the basis of its technology competences metal implants, bone cement and cementing techniques, orthobiological materials and electro-osteostimulation processes.

Insider Information according to Article 17 MAR dated June 06, 2002, 08:18 AM

aap Implantate AG is granted U.S. patent for Trauma Shoulder System

				
					

aap Implantate AG is granted U.S. patent for Trauma Shoulder System

Metal and biological implant specialist aap Implantate AG today announced that the U.S. Patent and Trademark Office has granted it a new patent for the Trauma Shoulder System (TSS). U.S. Patent No. 09/672,322, entitled Shoulder Joint Endoprosthesis, applies to the unique fixing mechanism of the prosthesis to the shoulder muscles on the upper arm. The patent was applied for in 2000. Data Monitor estimates that aap has gained access with the TSS patent to a potential U.S. market of roughly $ 93 million.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe Trauma Shoulder System opens up totally new ways of treating humerus head fractures because individual muscles are for the first time joined to the implant by a large number of multiple fixing points. This feature enables the surgeon to adjust the implant optimally to the anatomy of the individual patient.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe product has already been approved in the European market. Last year, aap estimates, the Trauma Shoulder System secured a market share of roughly 10% in Germany alone. Other TSS patents have been applied for in Europe and major Asian markets. aap Implantate AG currently has 35 patents and design patents in use. They cover aap's four technology competencies high-tech metal processing, bone cement and cementing techniques, orthobiological materials and electro-osteostimulation processes.

Insider Information according to Article 17 MAR dated May 31, 2002, 07:32 AM

aap boosts sales and earnings significantly

				
					

aap boosts sales and earnings significantly

START_OF_TAGiEND_OF_TAGProfitable growth in Q1 / Triple-digit earnings growth / First quarter confirms success of restructuring program / New products with attractive growth potentialSTART_OF_TAG/iEND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap Implantate AG testifies with its sales and earnings figures for the first quarter of 2002 to profitable growth that is well above the market level. First-quarter sales revenues increased by roughly 15% on the year to approx. EUR 3.42 million from EUR 2.98 million. EBITDA excluding stock options improved by 118% to EUR 1.2 million (previous year: EUR 540,000). Excluding acquisition-related write-downs totaling EUR 365,000 (previous year: EUR 403,000) and EUR 170,000 of stock options exercised and booked as expenses (previous year: EUR 208,000), EBIT amounts to EUR 895,000, up 286% on the previous year's EUR 232,000. The consolidated DVFA/SG result adjusted to take these factors into account was EUR 380,000 in the review period (previous year: EUR 24,000) and DVFA/SG earnings per share were EUR 0.08 (previous year: EUR 0.01). Cash earnings adjusted in the same way totaled EUR 535,000 (previous year: EUR 372,000). Taking into account the above-mentioned special effects (stock options and acquisition-related write-downs), the figures are as follows. EBITDA increased to EUR 1.0 million (previous year: EUR 332,000). EBIT increased markedly by EUR 740,000 to EUR 361,000 (previous year: -EUR 379,000). The consolidated DVFA/SG result for the review period, EUR 34,000, was substantially higher than the previous year's - EUR 355,000. DVFA/SG earnings per share were EUR 0.01 (previous year: -EUR 0.07). DVFA/SG cash earnings also improved in the review period to EUR 553,000 (previous year: EUR 395,000).

Issuer's information/explanatory remarks concerning this ad-hoc-announcement:START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGFirst-quarter progress reconfirms the successes of consistent enterprise-wide implementation of the restructuring program. The program is focused on cost optimization, sustained strengthening of the sales organization, integration of acquisitions, streamlining of the product portfolio and expansion in promising fields of competence. Strategic objectives for aap Implantate AG in the current financial year include intensifying sales activities in high-margin, high-growth foreign markets and extending product competencies into the orthobiological materials and bone cement/cementing technique segments. The bone replacement materials Cerabone, Cerabone granulate and Ostim that have already been granted approvals for the European market and are in the process of being launched constitute the starting-point for the extension of product competencies in this segment.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGOn the basis of the positive trend that is already emerging after the first quarter and of successes so far achieved with the restructuring program, aap reconfirms its forecast of profitable double-digit sales growth excluding special effects (stock options and acquisition-related write-downs) for the full year 2002.

Insider Information according to Article 17 MAR dated May 22, 2002, 09:39 AM

aap Implantate AG: Interim Q1 2002 figures

				
					

aap Implantate AG: Interim Q1 2002 figures

START_OF_TAGiEND_OF_TAG15% growth in sales revenues / EBITDA increase ex stock option 118% / Turnaround already achieved / Restructuring program shows clear successesSTART_OF_TAG/iEND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap Implantate AG, the metal and biological implant specialist for the muscular-skeletal system, increased sales revenues in the first quarter of 2002 by roughly 15% on the year to approximately EUR 3.42 million from EUR 2.98 million. EBITDA excluding stock options was up roughly 118% to roughly EUR 1.2 million (previous: EUR 540,000). Not counting acquisition-related depreciations totaling EUR 365,000 (previous: EUR 403,000) and stock options totaling EUR 170,000 (previous: EUR 208,000), EBIT amounted to EUR 895,000 (previous: EUR 232,000). Including the above-mentioned special effects (stock options and acquisition-related depreciations), EBIT was EUR 361,000 (previous: -EUR 379,000).START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe figures reconfirm the previously stated outlook for 2002 of double-digit growth in sales revenues and a net profit for the year without the above-mentioned special effects. aap Implantate AG will be announcing detailed figures on May 31 when the 3 monthly report is published.

Insider Information according to Article 17 MAR dated May 13, 2002, 08:37 AM

aap gains CE approval for knee endoprosthetics sector

				
					

aap gains CE approval for knee endoprosthetics sector

Metal and biological implant specialist aap Implantate AG has received European certification for an innovative knee endoprosthesis and, accordingly, for the knee endoprosthetics sector. The new knee endoprosthesis was taken to market maturity by aap as part of a development contract for Munich-based HJS Gelenk-System GmbH. In securing CE approval, aap has successfully completed a substantial part of the development contract.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe HJS implant makes almost natural movements possible by means of a surface geometry that has been patented worldwide. The interdisciplinary development team expects implant patients to be able to be able to move their knees after a relatively short time without pain once more and without major restrictions.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGData Monitor estimates the current total European market volume for knee endoprostheses to amount to roughly US $ 450 million. In combining the competence areas of shoulder, hip and knee endoprosthetics along with its already established cement and cement technology products, aap has succeeded in taking a decisive step toward becoming a single-point provider.

Insider Information according to Article 17 MAR dated March 28, 2002, 03:18 AM

aap Implantate AG publishes consolidated financial statements for 2001

				
					

aap Implantate AG publishes consolidated financial statements for 2001

aap Implantate AG publishes consolidated financial statements for 2001

 

START_OF_TAGiEND_OF_TAGConsolidated sales revenues approx. EUR 12 million (previous: approx. EUR 11 million) / EBITDA -EUR 1.171 million (previous: EUR 2.6 million) / Restructuring program achieves initial successes / Outlook for 2002: Return to profitabilitySTART_OF_TAG/iEND_OF_TAGSTART_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap Implantate AG, a life science company specialized in metal and biological implants for the musculoskeletal system, increased sales revenues last fiscal year by roughly 9% to approx. EUR 12 million from approx. EUR 11 million. It must however be borne in mind that the Mebio-Coripharm group companies acquired in fiscal 2000 were only consolidated pro rata from the fourth quarter. German sales revenues totaled EUR 9.3 million (previous: EUR 7.1 million) and were accordingly up by approx. 31%, so the company's market position in Germany was consolidated.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGEBITDA without taking stock options into account totaled -EUR 1.171 million (previous: EUR 2.6 million). Unadjusted for acquisition-related depreciations totaling EUR 1.436 million and stock options totaling EUR 804,000, the operating result fell to -EUR 2.399 million from EUR 1.596 million. The adjusted DVFA/SG consolidated result in the reporting period was -EUR 1.896 million (previous: EUR 888,000) and DVFA/SG earnings per share -EUR 0.40 (previous: EUR 0.21). Adjusted DVFA/SG cash earnings declined sharply to -EUR 737,000 (previous: EUR 2.141 million) in the reporting period. Taking into account the above-mentionedSTART_OF_TAGBREND_OF_TAGspecial effects (stock options and acquisition-related depreciation), the following figures apply: operating result down to -EUR 4.639 million from EUR 1.145 million. The DVFA/SG consolidated result was -EUR 3.372 million (previous: EUR 614,000) in the review period, DVFA/SG earnings per share were -EUR 0.71 (previous: EUR 0.15) and DVFA/SG cash earnings were -EUR 777,000 (previous: EUR 1.793 million).START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe main reasons for a revenues and earnings trend that fell short of plan were U.S. business below expectations, delays in approvals and certification procedures for biological implants and the failure of projected large orders anticipated from exclusive sales partners to materialize. In addition, planned R & D orders were postponed until the current financial year.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIssuer's information/explanatory remarks concerning this ad-hoc-announcement:START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGTo return to profitability this financial year the company embarked last year on a restructuring program consisting of extensive cost reduction measures and cross-group reorganization. Given the consistent implementation so far of the cross-group restructuring program, the turnaround planned for mid-2002 seemsSTART_OF_TAGBREND_OF_TAGlikely to occur after the first three months.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGFor the current fiscal year the Management Board anticipates double-digit growth in sales revenues and a positive operating result.


Insider Information according to Article 17 MAR dated March 07, 2002, 08:16 AM

approval for new bone replacement material in granulate form

				
					

approval for new bone replacement material in granulate form

approval for new bone replacement material in granulate form

 

aap subsidiary Coripharm has received CE approval for a granulate based on Cerabone bone ceramic. The currently prevailing treatment for filling defective bone is to use endogenous bone material. However, endogenous bone material is not always available in sufficient quantity. Now, Cerabone granulate can be mixed with the bone material to increase the available quantity of the patient's own bone. The granulate comes in three precisely defined grain sizes, making it suitable both for filling small cavities during dental, oral, orthodontic and facial surgery and for use in plastic surgery. The addition of this granulate to Coripharm's product portfolio also provides excellent opportunities for combination with other biological components such as growth factors.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGOne of the granulate's distinguishing features is a highly stable internally linked pore system that resembles the structure of human bone. Another special feature of this bone replacement material is that is it very well tolerated.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGMerrill Lynch estimates the market volume for all bone replacement materials used in orthopedics to total roughly $420 million. Some 50% of treatment performed in this field consists of replenishing lost bone with endogenous bone. Since the results of this form of treatment can be improved considerably using the granulate, aap sees a highly promising market potential.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGaap Implantate AG is an innovative company in the field of metallic and biological implants for the muscular-skeletal system. In securing CE approval of Cerabone granulate, aap has demonstrated yet again its speed of innovation in extending its new biological implant business field.


Insider Information according to Article 17 MAR dated February 28, 2002, 09:04 AM

CE approval for new nanotechnology-based bone matrix Ostim

				
					

CE approval for new nanotechnology-based bone matrix Ostim

Osartis, a company in which aap Implantate AG holds a 49% stake, has received CE approval for the new absorbable bone substitute material Ostim. Now the CE mark has been awarded, the wholly-owned aap subsidiary Mebio is to market the product. The wholly synthetic bone substitute represents a breakthrough byObernburg-headquartered Osartis GmbH & Co. KG in the development of innovative medical products. Using nanotechnology, a technology based on tiny functional units, a calcium phosphate was developed that is very similar in composition to the mineral found in human bones. Ostim speeds up the generation of bone-START_OF_TAGBREND_OF_TAGbuilding cells, thereby helping bones to regenerate. The new bone matrix can also be used for fractures of carrying skeletal parts such as thigh and lower leg bones, so it covers a very wide range of indications. The product is for use in treating bone defects in orthopedics, traumatology, dental, oral, maxillary and neurosurgery. It can be applied easily for a form fit using a standard syringe. Ostim is fully absorbed by the body.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGCE approval marks the expansion by aap of its product range into the new biological implant segment. Annual world market volume for all bone replacement materials used in orthopedics is said by Merrill Lynch currently to amount to roughly $420 million. By 2003, the world market for bone substitutes is expected to be worth up to $700 million, with annual growth rates of between 40% and 45%. With Ostim aap subsidiary Osartis has set a new standard in bone regeneration and succssfully established itself in the future-oriented nanotechnology market. The aap Group's established sales structure will form the basis for a successful market launch of the new bone substitute material. Marketing and sales activities for Ostim are to start immediately. In securing CE approval of Ostim the aap group of companies has reached a further milestoneSTART_OF_TAGBREND_OF_TAGon its way toward market leadership in biomaterials-based implants for orthopedic uses.START_OF_TAGBREND_OF_TAG


Insider Information according to Article 17 MAR dated December 10, 2001, 12:00 AM

aap subsidiary Coripharm agrees on sales agreement with Essex Chemie AG

				
					

aap subsidiary Coripharm agrees on sales agreement with Essex Chemie AG

aap subsidiary and biomaterialist specialist Coripharm Medizinprodukte GmbH & Co KG has agreed to terms that provide Swiss-based Essex Chemie AG exclusive European sales rights for the EASYMIX(r) vacuum cementing system. Vacuum cementing systems help ensure optimal preparation of bone cements for clinicalSTART_OF_TAGBREND_OF_TAGuse.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGEssex Chemie AG of Lucerne, Switzerland, is an indirectly-held subsidiary of Schering-Plough Corporation, an international health care group listed on the New York Stock Exchange. With annual sales (2000) of $9.8bn, Schering-Plough is one of the world's leading drug corporations.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe sales agreement will enable aap Group company Coripharm and Essex Chemie AG to supply the EASYMIX(r) vacuum cementing system throughout the European market for vacuum cementing techniques. With this new agreement, aap's Coripharm aims to underpin its position as one of the leading European suppliers of vacuum cementing systems. aap's long-term objective is to take on a leading role in theSTART_OF_TAGBREND_OF_TAGbiomaterials for orthopedic applications segment.START_OF_TAGBREND_OF_TAG

Insider Information according to Article 17 MAR dated November 30, 2001, 12:00 AM

aap announces Q3 results

				
					

aap announces Q3 results

  • Sales revenues up 30%


  • Adjustment of sales and earnings expectations


  • Restructuring program already under way


aap Implantate AG reports a further increase in sales revenues to DM17.8m from DM13.7m last year. Total operating performance improved by roughly 32% on the year to DM21.3m from about DM16.1m. EBITDA excluding stock options totaled DM1.1m (previous: DM3.8m). Not counting acquisition-related goodwillSTART_OF_TAGBREND_OF_TAGamortizations amounting to DM2.2m and stock options totaling DM1.2m, figures for the first nine months of 2001 are as follows: The operating result was down to -DM766,000 from last year's DM2.8m.START_OF_TAGBREND_OF_TAGThe DVFA/SG consolidated result for the review period was -DM1.4m (previous: DM1.5m). Third-quarter DVFA/SG earnings per share were -DM0.30 (previous: DM0.40) and Q3 cash earnings amounted to DM480,000 (previous: DM2.5m). After special effects the figures were as follows: Operating result down to -DM4.2m from DM2.8m in the same period last year, DVFA/SG consolidated result -DM3.8m (previous: DM1.5m), DVFA/SG earnings per share -DM0.80 (previous: DM0.40), DVFA/SG cash earnings DM403,000 (previous: DM2.5 m).START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGTo ensure future success the Management Board has put in place a restructuring program. In addition to a marked reduction in personnel costs and the identification and utilization of cost synergies it provides for across-the-board group reconstruction. As a part of these measures the company has announced that Joachim Staub, board member in charge of marketing and sales, is leaving the board as of Nov. 30, 2001. From Dec. 1, 2001 board chairman and CEO Uwe Ahrens will take over responsibility for marketing and sales in addition to his other duties. In addition, the post of sales and marketing director has been set up and an in-house appointment has already been made.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGend of ad-hoc-announcement (c)DGAP 30.11.2001START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGIssuer's information/explanatory remarks concerning this ad-hoc-announcement:START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGReasons why sales revenues and earnings have fallen short of the plan in the financial year in progress include U.S. business, which has failed to live up to expectations, time delays in approvals and certification procedures for biological implants, anticipated large orders by exclusive sales partners either failing to materialize or being postponed, and proposed R&D contracts being held over until fiscal 2002. Due toSTART_OF_TAGBREND_OF_TAGthe difficult situation in the capital market, especially in the Neuer Markt segment, aap has, moreover, had noSTART_OF_TAGBREND_OF_TAGopportunity to refinance during the review period. For that reason the company decided to hold over until the next financial year a proposed acquisition project. In view of these factors aap forecasts for the full financial year in progress sales revenues of between DM23m and DM25m and EBIT excluding special effects expected to be better than - DM1.9m.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGTo continue with the present growth strategy and to achieve with it a clearly positive result in 2002 the company has embarked on a restructuring program that involves extensive cost reduction measures and reconstruction throughout the group. Solely by means of restructuring measures already implemented, especially within the framework of personnel reductions, the company will cut costs by at least DM2m in 2002. By dint of resolute cost management and stepping up of sales activities, especially for new products, the management anticipates sales growth of between 45% and 50% in 2002.START_OF_TAGBREND_OF_TAGSTART_OF_TAGBREND_OF_TAGThe Management Board reaffirms its strategy of tapping the great potential of orthobiology as a market of the future by boosting the biomaterials segment. aap's long-term objective continues, in addition to increasing business in metal implants, to be that of achieving market leadership in orthopedical applications based on biomaterials.START_OF_TAGBREND_OF_TAG

Cookies

We wish to provide you with website usage that protects your data privacy and also inform you of the plug-ins and cookies we use. They help us tailor content and advertising to you as an individual and to make our website better, quicker, and more secure. You can learn which cookies we use and how you can deactivate them, and get additional information regarding protection of data privacy on our website, in our Data Privacy Policy. You can reject the usage of third-party cookies by clicking the "Reject" button.